|
|
|
|
|
•
|
Leading with ULTOMIRIS by raising the standard of care for rare disease patients in the indications we treat and continuing to innovate with new ULTOMIRIS formulations
|
•
|
Expanding our C5-targeted franchise, which includes SOLIRIS and ULTOMIRIS, beyond our legacy indications of PNH and aHUS into new rare diseases and expanded disease areas, including neurology
|
•
|
Diversifying our current portfolio by pursuing new rare disease opportunities in strategic adjacencies and in doing so, providing hope for patients that are currently underserved
|
•
|
Protecting patient and customer safety and medicine supply continuity;
|
•
|
Ensuring safety and a sense of security for people who work at Alexion;
|
•
|
Safeguarding our manufacturing, distribution and research facilities;
|
•
|
Maintaining the integrity of our clinical trials and commitment to data quality;
|
•
|
Responsibly supporting our community and local healthcare systems; and
|
•
|
Remaining nimble and responsive to the everchanging situation while always remaining true to our core values.
|
(1)
|
To elect the ten members of the Board of Directors named in the proxy statement, each to serve until the next Annual Meeting and until his or her successor has been duly elected and qualified.
|
(2)
|
To ratify the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm for 2020.
|
(3)
|
To consider a non-binding advisory vote on 2019 compensation paid to Alexion's named executive officers.
|
(4)
|
To vote upon a shareholder proposal, if properly presented at the 2020 Annual Meeting, requesting that the Board amend the provisions set forth in Alexion's By-laws to lower the threshold for shareholders to call a special meeting of shareholders.
|
(5)
|
To transact such other business as may properly come before the 2020 Annual Meeting or any adjournment thereof.
|
Table Of Contents
|
|
|
|
|
Page
|
|
Proxy Statement Summary
|
Date:
|
May 13, 2020
|
Time:
|
5:30 p.m. local time
|
Place:
|
The Seaport Hotel, 1 Seaport Lane, Boston MA 02210
|
Record Date:
|
March 16, 2020
|
Voting Matter
|
Board Recommendation
|
Page Number for More Detail
|
|
Proposal 1
|
Election of Directors
|
FOR ALL Nominees
|
|
Proposal 2
|
Ratification of PricewaterhouseCoopers LLP as Independent Auditors
|
FOR
|
|
Proposal 3
|
Non-binding Advisory Vote to Approve Executive Compensation
|
FOR
|
|
Proposal 4
|
Shareholder Proposal
|
AGAINST
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
1
|
Board and Board Committees*
|
|
Number of directors on Board
|
10
|
Number of independent directors
|
9
|
Average director tenure (in years)
|
4.4
|
Average age of directors
|
63.1
|
All Board Committees consist of independent directors
|
Yes
|
Risk oversight by Board and Committees
|
Yes
|
Active Audit Committee Oversight of Enterprise Risk Management
|
Yes
|
Separate Chairman and CEO
|
Yes
|
"Rooney Rule" adopted for filling open Board positions
|
Yes
|
Regular executive sessions of independent directors
|
Yes
|
Annual Anonymous Board and Committee evaluations
|
Yes
|
Anti-Overboarding policy limiting the number of public company boards on which a director may serve
|
Yes
|
Annual Independent Director Evaluation of CEO
|
Yes
|
Director Education Program
|
Yes
|
Annual equity grant to directors
|
Yes
|
Director has the option to take annual cash retainer in equity
|
Yes
|
Shareholder Rights, Accountability and Other Governance Practices
|
|
Annual elections for all directors
|
Yes
|
Majority voting for directors
|
Yes
|
Proxy access bylaw (3%-3 years, nominees up to 20% of our Board)
|
Yes
|
Annual advisory vote on executive compensation
|
Yes
|
Shareholder ability to call special meetings (25% threshold)
|
Yes
|
Shareholder ability to act by written consent
|
Yes
|
Stock ownership guidelines for directors and executives
|
Yes
|
Prohibition from hedging and pledging securities or otherwise engaging in derivative transactions
|
Yes
|
Comprehensive Code of Conduct and Corporate Governance Guidelines
|
Yes
|
Nominating and Corporate Governance Committee oversight of Corporate Social Responsibility (CSR) and Publication of Annual CSR Report
|
Yes
|
Commitment to Environmental and Sustainability Matters
|
Yes
|
Board Oversight and Disclosure on Website Related to Corporate Political Contributions and Expenditures
|
Yes
|
Clawback policy applies to executive compensation
|
Yes
|
Absence of Rights Plan, or “Poison Pill”
|
Yes
|
Absence of supermajority voting provisions
|
Yes
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
2
|
Nominee, Experience
|
Age
|
Director Since
|
Committees
|
Other Public Boards
|
|||
AF
|
LC
|
NG
|
SI
|
||||
Felix J. Baker
Co-Managing Member of Baker Bros. Advisors
|
51
|
2015
|
|
|
X
|
C
|
3
|
David R. Brennan
Independent Chairman, Former Interim Chief Executive Officer of Alexion, Former Chief Executive Officer of AstraZeneca PLC
|
66
|
2014
|
|
X
|
X
|
|
1
|
Christopher J. Coughlin
Former Executive Vice President and Chief Financial Officer, Tyco
|
67
|
2014
|
C, F
|
X
|
|
|
2
|
Deborah Dunsire
Chief Executive Officer, H. Lundbeck A/S
|
57
|
2018
|
|
X
|
|
X
|
1
|
Paul A. Friedman
Chief Executive Officer, Madrigal Pharmaceuticals
|
77
|
2017
|
|
|
X
|
X
|
2
|
Ludwig N. Hantson
Chief Executive Officer
|
57
|
2017
|
|
|
|
|
1
|
John T. Mollen
Former Executive Vice President, Human Resources of EMC Corp.
|
69
|
2014
|
X
|
C
|
|
|
_
|
Francois Nader
Former President and Chief Executive Officer, NPS Pharma
|
63
|
2017
|
X, F
|
|
|
X
|
3
|
Judith A. Reinsdorf
Former Executive Vice President and General Counsel, Johnson Controls
|
56
|
2018
|
X
|
|
C
|
|
_
|
Andreas Rummelt
Chief Executive Officer of InterPharmaLink AG
|
63
|
2010
|
|
|
X
|
X
|
_
|
Fees
|
2019
|
2018
|
Audit fees
|
$5,333,815
|
$4,384,965
|
Audit-related fees
|
$5,000
|
$229,840
|
Tax fees
|
$40,000
|
$110,334
|
All other fees
|
$9,900
|
$9,900
|
Total fees
|
$5,388,715
|
$4,735,039
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
3
|
Pay-for-Performance
|
Compensation is tied to the achievement of the Company’s short- and long-term financial, operational and strategic objectives that are designed to support shareholder value creation and our long-term objectives
|
A substantial portion of our annual cash bonus determinations have been based on the achievement of pre-established financial performance goals (and such goals have accounted for an increasing percentage of the target cash bonus) - 0% weighting for 2016, 50% for 2017 and 65% for 2018, 2019 and 2020
|
Since 2016, we have increased the portion of long-term incentives delivered in performance share units (PSUs) - 25% PSUs for 2016, 50% for 2017 and 65% for 2018, 2019 & 2020 (based on grant date value at target)
|
Other Executive Compensation Practices
|
The Leadership and Compensation Committee provides competitive total pay opportunities after consideration of many factors, including our strategy for enhancing shareholder value and long-term performance and a review of comparative market data
|
We maintain a clawback policy under which cash-and equity-based incentive compensation of our Chief Executive Officer (CEO) and other executive officers may be recovered by Alexion under certain circumstances in the event of a financial restatement
|
Compensation risk assessments are conducted annually by the Leadership and Compensation Committee
|
Options are not granted to executives or employees
|
Double-trigger equity vesting upon change in control
|
All employees, including directors and NEOs, are prohibited from entering into any hedging, pledging or derivative transactions in our stock
|
Our equity incentive plan prohibits the repricing or exchange of stock options without shareholder approval
|
The Leadership and Compensation Committee regularly reviews our share utilization levels and "burn rate"
|
NEOs are required to acquire and hold Alexion stock worth three to six times their base salary within five years of appointment
|
We do not provide 280G tax gross-ups
|
The Leadership and Compensation Committee retains an independent compensation consultant
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
4
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
5
|
General Information Regarding the Meeting
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
6
|
(1)
|
Elect the ten members of the Board of Directors named in the proxy statement, each to serve until the next Annual Meeting and until his or her successor has been duly elected and qualified.
|
(2)
|
Ratify the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm for 2020.
|
(3)
|
A non-binding advisory vote on 2019 compensation paid to Alexion's named executive officers.
|
(4)
|
A shareholder proposal, if properly presented at the 2020 Annual Meeting, requesting that the Board amend the provisions set forth in Alexion's By-laws to lower the threshold for shareholders to call a special meeting of shareholders.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
7
|
n
|
By Internet: Go to the Internet website – www.proxyvote.com – and follow the instructions. You must vote by 11:59 P.M. Eastern on May 12, 2020.
|
n
|
By Telephone: Call the toll-free number 800-690-6903 to vote by telephone. You must follow the instructions on your proxy card and the recorded telephone instructions. You must vote by 11:59 P.M. Eastern on May 12, 2020.
|
n
|
By Mail: Mark, sign and date the proxy card and return it promptly in the self-addressed, stamped envelope. If a proxy card is signed and returned without instructions, your shares will be voted in the manner recommended by our Board of Directors. Your proxy card must be received by May 12, 2020.
|
n
|
In Person: You can attend the 2020 Annual Meeting to vote by ballot.
|
n
|
filing a timely written notice of revocation with the Corporate Secretary, Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA 02210;
|
n
|
mailing a duly executed proxy bearing a later date;
|
n
|
re-voting by phone or the Internet prior to the date and time described in this proxy statement; or
|
n
|
voting in person at the 2020 Annual Meeting.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
8
|
|
|
Board's Recommendation
|
Broker Discretionary Voting Allowed
|
Abstentions
|
Required Vote
|
Proposal 1
|
Election of Directors
|
FOR ALL Nominees identified in this Proxy Statement
|
No
|
No effect
|
Majority of votes cast
|
Proposal 2
|
Ratification of PricewaterhouseCoopers LLP as independent auditors for 2020
|
FOR
|
Yes
|
No effect
|
Majority of votes cast
|
Proposal 3
|
Non-binding Advisory Vote on 2019 Executive Compensation
|
FOR
|
No
|
No effect
|
Majority of votes cast
|
Shareholder Proposal
|
|
|
|
|
|
Proposal 4
|
Requesting that the Board Amend Alexion's By-laws to Lower the Threshold to call a special meeting
|
AGAINST
|
No
|
No effect
|
Majority of votes cast
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
9
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
10
|
Proposal No. 1 – Election Of Directors
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
11
|
General Information About The Board Of Directors
|
•
|
Nine of our 10 directors have years of C-suite level experience, with 6 current or former CEOs;
|
•
|
Eight of 10 directors have experience working for pharmaceutical or biopharmaceutical companies (and the final two directors are: an investment advisor focused on investments in life science and biotechnology companies and a former human resources executive who brings critical insight and experience to the design of our executive compensation program);
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
12
|
•
|
All 10 directors have experience acquiring and/or divesting businesses and technologies and evaluating strategic corporate decisions; and
|
•
|
All directors bring unique specialties to the Board, including biotech/pharmaceuticals investing experience, quality and manufacturing, human resources, compensation design and implementation, legal and compliance, public accounting expertise, medical research and product research and development.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
13
|
David R. Brennan, Chairman of the Board
|
|
|
Age: 66
|
|
Mr. Brennan served as Interim Chief Executive Officer of Alexion from December 11, 2016 to March 27, 2017. From 2006 to 2012, he was Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world’s largest pharmaceutical companies. Mr. Brennan worked for Astra Merck, Astra, and AstraZeneca in increasing roles of responsibility from 1992 through 2012, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck. He received a BA in business administration from Gettysburg College, where he is the Chairman of the Board of Trustees.
|
Alexion Director Since: 2014
|
|
|
Committee Memberships: Leadership and Compensation, Nominating and Corporate Governance
|
|
|
Other Public Company Directorships
|
|
|
Current: Insmed Incorporated
|
|
|
Past 5 Years: Innocoll Holdings plc
|
|
|
|
|
|
Qualifications
|
|
|
n Extensive experience as an executive leader in the pharmaceutical industry, serving as chief executive officer of one of the largest multinational pharmaceutical companies in the world
|
|
|
n Significant industry and regulatory knowledge from a more than 39 year career in the pharmaceutical industry and serving as a director on multiple public company and industry trade group boards
|
|
|
n Extensive experience evaluating and developing complex strategic business plans
|
|
|
n Brings valued operational perspectives to the Board on matters of talent recruiting and development, executive compensation, benefits and leadership
|
|
|
n Extensive global and M&A experience
|
|
Christopher J. Coughlin
|
|
|
Age: 67
|
|
Mr. Coughlin served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010, during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to1998, he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin received a BS in accounting from Boston College. Mr. Coughlin is an audit committee financial expert.
|
Alexion Director Since: 2014
|
|
|
Committee Memberships: Audit and Finance (Chair), Leadership and Compensation
|
|
|
Other Public Company Directorships
|
|
|
Current: Allergan plc, Prestige Consumer Healthcare Inc.
|
|
|
Past 5 Years: Covidien Ltd., Dun & Bradstreet Corp., Dipexium Pharmaceuticals, Forest Laboratories, Hologic Inc.
|
|
|
|
|
|
Qualifications
|
|
|
n Extensive experience in complex financial and accounting matters, including public accounting and reporting
|
|
|
n Extensive experience evaluating and developing strategic goals for global organizations
|
|
|
n Broad experience serving on public international and domestic company boards provides valued perspective on corporate governance and financial matters
|
|
|
n Extensive operational experience managing complex global organizations
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
14
|
Deborah Dunsire
|
|
|
Age: 57
|
|
Since September 1, 2018, Dr. Dunsire has served as President and Chief Executive Officer of H. Lundbeck A/S. From 2005 to 2013, Dr. Dunsire served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc., where she led the transformation of the company into a biotechnology industry leader. Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led the Novartis North America Oncology Business through a period of significant growth during her 10-year tenure. She also previously served as President and Chief Executive Officer of FORUM Pharmaceuticals and in a variety of Research and Development and Commercial positions with Sandoz AG. From January 2017 until March 2017, Dr. Dunsire served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., a privately held biopharmaceutical company developing novel therapeutics. Dr. Dunsire received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.
|
Alexion Director Since: 2018
|
|
|
Committee Memberships: Science and Innovation, Leadership and Compensation
|
|
|
Other Public Company Directorships
|
|
|
Current: Ultragenyx Pharmaceutical, Inc.
|
|
|
Past 5 Years: Allergan Inc., Takeda Pharmaceuticals, Inc.
|
|
|
|
|
|
Qualifications
|
|
|
n More than thirty years of experience in the biopharmaceutical industry
|
|
|
n Brings value to the Board through experience as a chief executive officer of innovative companies focused on drug research and development
|
|
|
n Extensive experience leading complex drug discovery, development and commercialization organizations
|
|
|
n Possesses deep scientific and medical expertise
|
|
Paul Friedman
|
|
|
Age: 77
|
|
Since July 2016, Dr. Friedman has served as Chairman of the Board of Directors and Chief Executive Officer of Madrigal Pharmaceuticals. Dr. Friedman served as the CEO and a Director of Incyte Corporation from November 2001 until his retirement in January 2014. He served as President of Research & Development for the DuPont-Merck Pharmaceutical Company, and also as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company. He has also held executive and R&D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories, and Merck Sharp & Dohme Corporation. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.
|
Alexion Director Since: 2017
|
|
|
Committee Memberships: Nominating and Corporate Governance, Science and Innovation
|
|
|
Other Public Company Directorships
|
|
|
Current: Incyte Corporation, Madrigal Pharmaceuticals, Inc.
|
|
|
Past 5 Years: Cerulean Pharmaceuticals, Inc., Synta Pharmaceuticals, Inc., Verastem Pharmaceuticals
|
|
|
|
|
|
Qualifications
|
|
|
n More than 40 years of experience in the biopharmaceutical industry
|
|
|
n Deep experience in research and both early and late stage clinical development
|
|
|
n Extensive experience building and leading R&D organizations, expanding company pipelines of assets, and overseeing the commercial development of innovative therapeutic products across a range of areas
|
|
|
n Brings valuable perspectives to the Board as a chief executive officer in the biopharmaceutical industry
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
15
|
Ludwig N. Hantson
|
|
|
Age: 57
|
|
Dr. Hantson became Chief Executive Officer of Alexion on March 27, 2017. Prior to joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated. He led Baxalta’s successful spin-off as a public company from Baxter International Inc. in July 2015 where he was President of Baxter BioScience. He joined Baxter in May 2010 and established the BioScience division as an innovative specialty and rare disease company with a pipeline of 25 new product candidates, and 13 product launches. Prior to Baxter, from 2001 to 2010, Dr. Hantson held several leadership roles at Novartis AG, including CEO of Pharma North America, CEO of Europe, and President of Pharma Canada. Prior to Novartis, Dr. Hantson spent 13 years with Johnson & Johnson in roles of increasing responsibility in marketing and research and development. Dr. Hantson received his Ph.D. in motor rehabilitation and physical therapy, Master’s degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.
|
Alexion Director Since: 2017
|
|
|
Committee Memberships: None
|
|
|
Other Public Company Directorships
|
|
|
Current: Hologic, Inc.
|
|
|
Past 5 Years: Baxalta Incorporated, Baxter International Inc.
|
|
|
|
|
|
Qualifications
|
|
|
n More than 30 years of experience in the biopharmaceutical industry
|
|
|
n Extensive experience as an executive leading global, innovative organizations
|
|
|
n Deep development, regulatory and commercial experience in the biopharmaceutical industry
|
|
|
n Chief Executive Officer of Alexion
|
|
John T. Mollen
|
|
|
Age: 69
|
|
Mr. Mollen served as Executive Vice President, Human Resources of EMC Corporation from May 2006 until his retirement in February 2014, including two years as special advisor to the President. He joined EMC as Senior Vice President, Human Resources in September 1999. Prior to joining EMC, Mr. Mollen was Senior Vice President of Human Resources with Citigroup Inc., a financial services company, from July 1997 to September 1999. Prior to Citigroup, he held a number of positions of increasing responsibility with Harris Corp., an international communications and technology company, including Vice President of Administration. Mr. Mollen serves as a director for a number of not-for-profit and professional boards, including the New England Healthcare Institute, the HR Policy Association, and the Center on Executive Compensation, and is an advisory board member for Working Mother magazine, and he is Chairman of the Board of Trustees of Worcester Polytechnic Institute. Mr. Mollen received a B.A. in Economics from St. John Fisher College, and a Master's degree in Labor Relations from St. Francis College in Pennsylvania.
|
Alexion Director Since: 2014
|
|
|
Committee Memberships: Audit and Finance, Leadership and Compensation (Chair)
|
|
|
Other Public Company Directorships
|
|
|
Current: None
|
|
|
Past 5 Years: None
|
|
|
|
|
|
Qualifications
|
|
|
n Significant experience in executive compensation policy and administration
|
|
|
n More than 30 years as chief human resources senior executive
|
|
|
n Extensive operational experience leading human resource function for large, public, complex, global organizations, including a Fortune 200 company
|
|
|
n Brings valued operational perspectives to the Board on matters of talent recruiting and development, executive compensation, benefits and leadership
|
|
|
n Extensive global and deep M&A experience
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
16
|
Francois Nader
|
|
|
Age: 63
|
|
Dr. Nader served as President, Chief Executive Officer, and Executive Director of NPS Pharma, a global biotechnology company that was focused on delivering innovative therapies to patients with rare diseases, from 2008 to 2015. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on the North America Leadership Team of Aventis Pharma and its predecessor companies, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. He also led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee. Dr. Nader is an audit committee financial expert.
|
Alexion Director Since: 2017
|
|
|
Committee Memberships: Audit and Finance, Science and Innovation
|
|
|
Other Public Company Directorships
|
|
|
Current: Acceleron Pharma, Inc., Moderna, Inc., Prevail Therapeutics Inc.
|
|
|
Past 5 Years: Clementia Pharmaceuticals, Inc., Advanced Accelerator Applications, Inc., Baxalta Incorporated, NPS Pharmaceuticals, Inc., Trevena, Inc.
|
|
|
|
|
|
Qualifications
|
|
|
n Extensive experience in the biopharmaceutical industry
|
|
|
n Broad experience with organizations focused on developing and launching rare disease therapies
|
|
|
n Experienced biopharmaceutical chief executive officer with strong background across both commercial and R&D functions
|
|
|
n Deep experience investing in biotechnology companies providing valuable insight in evaluating internal development product initiatives and external opportunities
|
|
Judith Reinsdorf
|
|
|
Age: 56
|
|
Ms. Reinsdorf previously served as Executive Vice President and General Counsel of Johnson Controls International, a global leader in building products and technology and integrated solutions from September 2016 to November 2017, following its merger with Tyco International, where she served as Executive Vice President and General Counsel from March 2007 until September 2016. Prior to Johnson Controls, Ms. Reinsdorf served as Vice President, General Counsel and Secretary of C. R. Bard, Inc., as Vice President and Corporate Secretary of Tyco, as Vice President and Associate General Counsel of Pharmacia Corporation, and as Assistant General Counsel and Chief Legal Counsel, Corporate, at Monsanto Company. Ms. Reinsdorf earned her bachelor’s degree from the University of Rochester and her J.D. from Cornell Law School.
|
Alexion Director Since: 2018
|
|
|
Committee Memberships: Audit and Finance, Nominating and Corporate Governance (Chair)
|
|
|
Other Public Company Directorships
|
|
|
Current: None
|
|
|
Past 5 Years: Dun & Bradstreet Corp.
|
|
|
|
|
|
Qualifications
|
|
|
n Brings strong corporate governance, compliance and legal expertise to the Board
|
|
|
n Broad experience in global compliance, strategic planning, data privacy, and regulatory matters
|
|
|
n Extensive experience leading legal functions at large U.S. public companies with global operations and in regulated industries
|
|
|
n Extensive global and deep M&A experience
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
17
|
Andreas Rummelt
|
|
|
Age: 63
|
|
Dr. Rummelt has served as the Chief Executive Officer of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry, since January 2011. From December 2008 until January 2010, Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis. He had been a member of the Executive Committee of Novartis from January 2006 until his resignation in January 2010. He joined Sandoz Pharma Ltd. in 1985 and held various positions of increasing responsibility in pharma development. In 1994, he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger that created Novartis in 1996. From 1999 to 2004, Dr. Rummelt served as Head of Technical Operations of the Novartis Pharmaceuticals Division and from 2004 to 2008 as Global CEO of Sandoz. Dr. Rummelt graduated with a Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuernberg, Germany.
|
Alexion Director Since: 2010
|
|
|
Committee Memberships: Nominating and Corporate Governance, Science and Innovation
|
|
|
Other Public Company Directorships
|
|
|
Current: None
|
|
|
Past 5 Years: None
|
|
|
|
|
|
Qualifications
|
|
|
n More than 25 years in the areas of pharmaceutical manufacturing, quality and technical development, providing an important perspective to the Board and to management
|
|
|
n More than 20 years in executive management positions in the pharmaceutical industry, including as a chief executive officer and as a senior executive of a large, multinational pharmaceutical company
|
|
|
n Possesses a broad understanding of international business operations, particularly with respect to manufacturing, quality and technical matters
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
18
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
19
|
•
|
GlaxoSmithKlein plc’s acquisition of AstraZeneca plc’s OTC products (2009)
|
•
|
Gurnet Point Capital’s acquisition of Innocoll Holdings plc (2017)
|
•
|
AstraZeneca plc’s acquisitions of Cambridge Antibody Technology (2006), MedImmune (2007) and Novexel SA (2009)
|
•
|
MedImmune LLC’s acquisitions of AlphaCore Pharma LLC (2013), Amplimmune, Inc. (2013) AZ and Spirogen Ltd. (2013), Allozyne, Inc. (2014) and Definiens AG (2014)
|
•
|
Nordic Capital and Avista Capital Holding’s acquisition of a majority stake in Acino Holding AG (2013)
|
•
|
Rentschler Biotechnologie GmbH‘s acquisition of a minority stake in LeukoCare AG (2017)
|
•
|
Novo A/S’s acquisition of Xellia Pharmaceuticals AS (2013)
|
•
|
Eurofins Group acquisition of Selcia Ltd. (2017)
|
•
|
Zentiva Group’s acquisition of the central and eastern European business of Alvogen (2019)
|
•
|
Novartis AG’s acquisition of Hexal AG and Eon Labs (2005)
|
•
|
Sandoz AG’s acquisition of Ebewe (2009)
|
•
|
CVC Capital Partner’s and Temasek’s acquisition of Alvogen (2015) (supported by InterPharmaLink AG)
|
•
|
Alvogen’s acquisition of County Line Pharmaceuticals (2016)
|
•
|
Abbvie, Inc’s pending acquisition of Allergan plc (2019)
|
•
|
Pfizer Inc.’s proposed acquisition of Allergan plc (2016)
|
•
|
Medtronic, Inc.’s acquisition of Covidien plc (2015)
|
•
|
Actavis plc’s acquisition of Forest Laboratories, Inc. (2014)
|
•
|
Pharmacia Corporation’s spin-off of Monsanto Company (2002)
|
•
|
Pharmacia's sale of a stake in Amersham Biosciences (2001)
|
•
|
Sanofi Group’s acquisition of Sterling Winthrop’s prescription drug business (1994)
|
•
|
Smithkline Beecham’s acquisition of Sterling Winthrop’s over-the-counter medicine’s business (1994)
|
•
|
Tyco International Ltd.’s sale of Tyco’s A&E Products Group to Apollo Global Management (2005)
|
•
|
Separation of Tyco International Ltd. (2012)
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
20
|
•
|
Actavis plc’s acquisition of Allergan plc (2015)
|
•
|
Allergan plc’s acquisitions of ForSight VISION5, Inc. (2016), LifeCell Corp. (2016), Motus Therapeutics, Inc. (2016), Tobira Therapeutics, Inc.(2016), Vitae Pharmaceuticals Inc. (2016), RetroSense Therapeutics LLC (2016), ZELTIQ Aesthetics, Inc. (2017), Bonti, Inc. (2018), Chase Pharmaceuticals Corp. (2018), Elastagen Pty Ltd. (2018)
|
•
|
Covidien plc’s acquisitions of Somanetics Corp. (2010), BÂRRX Medical, Inc. (2011), superDimension Ltd. (2012), CV Ingenuity Corp. (2012), Oridion Systems Ltd. (2012), Newport Medical Instruments, Inc. (2012), ev3, Inc. (2010) and Given Imaging Ltd. (2013), New Wave Surgical Corp. (2014)
|
•
|
Forest Laboratories, Inc.’s acquisition of Furiex Pharmaceuticals, Inc. (2014) and Aptalis Holdings, Inc. (2014)
|
•
|
Pharmacia’s acquisition of Sugen Inc. (1999)
|
•
|
Pharmacia’s merger with Monsanto Co. (2000)
|
•
|
Tyco International Inc.’s acquisition of Broadview Security (2010)
|
•
|
Actavis plc’s acquisition of Allergan plc (2015)
|
•
|
Valeant Pharmaceuticals/Pershing Square’s attempted acquisition of Allergan plc (2014)
|
•
|
Millennium Pharmaceuticals, Inc. performs market check in response to an unsolicited bid and decision made not to sell the company (2006)
|
•
|
Takeda Pharmaceutical Co. Ltd.’s acquisition of Millenium Pharmaceuticals, Inc. (2008)
|
•
|
Allergan plc’s acquisitions of MAP Pharmaceuticals, Inc. (2011), Vicept Therapeutics, Inc. (2011) and SkinMedica, Inc. (2012)
|
•
|
Allergan plc’s proposed acquisition of Salix Pharmaceuticals Ltd. (2014)
|
•
|
H. Lundbeck A/S’s acquisitions of Abide Therapeutics, Inc. (2019) and Alder Biopharmaceuticals, Inc. (2019)
|
•
|
Millennium Pharmaceuticals, Inc. proposed “white knight” acquisition of AnorMED, Inc. 2006)
|
•
|
Takeda Pharmaceutical Co. Ltd.’s acquisition of Nycomed (2011) and Intellikine (2011)
|
•
|
Ultragenyx Pharmaceutical, Inc.’s acquisition of Dimension Therapeutics, Inc. (2017)
|
•
|
AstraZeneca plc’s acquisition of Ardea Biosciences, Inc. (2012)
|
•
|
EXACT Sciences Corp.’s acquisition of Genomic Health, Inc. (2019)
|
•
|
Alexion Pharmaceutical, Inc.’s acquisition of Synageva BioPharma Corp. (2015)
|
•
|
Genzyme Corp.’s acquisition of AnorMED, Inc. (2006)
|
•
|
Seattle Genetics, Inc.’s acquisition of Cascadian Therapeutics, Inc. (2018)
|
•
|
Novartis AG’s acquisition of Advanced Accelerator Applications, SA (2018)
|
•
|
Ipsen Biopharmaceuticals’ acquisition of Clementia Pharmaceuticals Inc. (2019)
|
•
|
Shire plc’s acquisition of Baxalta, Inc. (2016)
|
•
|
Silicon Valley Bank’s acquisition of Leerink Holdings LLC (2018)
|
•
|
Hisamitsu Pharmaceutical Co., Inc.’s acquisition of Noven Pharmaceuticals, Inc. (2009)
|
•
|
Shire plc’s acquisition of NPS Pharmaceuticals, Inc. (2015)
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
21
|
•
|
Baxalta, Inc’s acquisition of Sigma Tau Finanziaria SpA’s Oncaspar Portfolio (2015)
|
•
|
Dell Inc.’s acquisition of EMC Corp. (2015)
|
•
|
EMC Corp.’s acquisition of Data General (2002), Documentum (2003), VMware, Inc. (2004), RSA Security (2006), Data Domain, Inc. (2009), Greenplum (2010), Pivotal Labs (2012)
|
•
|
Thomas H. Lee Partners LP’s acquisition of Dun & Bradstreet Corp. (2018)
|
•
|
Tyco International plc’s acquisition of Johnson Controls, Inc. (2016)
|
•
|
Johnson Controls, Inc. sale of Scott Safety to 3M Co. (2017)
|
•
|
Pfizer Inc.’s acquisition of Pharmacia Corporation (2003)
|
•
|
Tyco International Inc.’s spin-off of ADT Corp. (2012)
|
•
|
Dun & Bradstreet Corp.’s acquisitions of NetProspex, Inc. (2015) and Avention, Inc. (2017)
|
•
|
Pharmacia’s merger with Monsanto Co. (2000)
|
•
|
Tyco International Inc.’s acquisition of Broadview Security (2010)
|
•
|
Tyco International Inc.’s merger of Tyco Flow Control business into Pentair Ltd. (via reverse Morris trust) (2012)
|
•
|
Shire plc’s acquisition of Baxalta, Inc. (2016)
|
•
|
Baxter International Inc.’s spin off of Baxalta Inc. (2015)
|
•
|
Hologic Inc.’s divestiture of its Cynosure medical aesthetics business (2019)
|
•
|
Baxter International Inc.’s acquisitions of Archemix Corp. (2010), Baxa Corp. (2011), Prism Pharmaceuticals, Inc. (2011), Gambro AB (2012), AesRX LLC (2014), Chatham Therapeutics LLC (2014), SuppreMol GmbH (2015), Sigma-Tau Pharma Ltd. (2015)
|
•
|
Baxalta Inc.’s acquisition of Sigma Tau Finanziaria SpA’s Oncaspar Portfolio (2015)
|
•
|
Hologic, Inc.’s acquisition of a minority stake in SuperSonic Imagine (2019)
|
•
|
Novartis International AG’s acquisition of Alcon Laboratories, Inc. (2008)
|
•
|
Endo International plc’s acquisition of Auxilium Pharmaceuticals LLC (2014)
|
•
|
Warburg Pincus’s acquisition of Bausch & Lomb, Inc. (2007)
|
•
|
Actavis plc’s acquisition of Durata Therapeutics, Inc. (2014)
|
•
|
Auxilium Pharmaceuticals LLC’s acquisition of Actient Pharmaceuticals LLC (2013)
|
•
|
Synta Pharmaceuticals Corp.’s acquisition of Madrigal Pharmaceuticals, Inc. (2016)
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
22
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
23
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
24
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
25
|
Corporate Governance
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
26
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
27
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
28
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
29
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
30
|
•
|
change in certain external job responsibilities;
|
•
|
existence of a significant conflict of interest that cannot be resolved; and
|
•
|
in the case the director is also Alexion's CEO, upon resignation from the position as a corporate officer at Alexion.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
31
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
32
|
•
|
Call meetings of the independent directors, preside over all such meetings and reports to the Board, as appropriate, concerning such meetings.
|
•
|
Review Board agendas in collaboration with the Chairman and recommends matters for the Board to consider and information to be provided to the Board.
|
•
|
Serve as an independent point of contact for shareholders wishing to communicate with the Board other than through the Chairman.
|
•
|
Assist in optimizing the effectiveness of the Board and ensure that it operates independently of our executive team.
|
•
|
In an advisory capacity, evaluate the executive team’s processes for periodically reviewing, refreshing and modifying its enterprise risk management system and processes;
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
33
|
•
|
Oversee the Company’s efforts to foster a culture of risk-adjusted decision-making without constraining reasonable risk-taking and innovation;
|
•
|
Review with the executive team, internal auditors and external advisors the identification, prioritization and management of the risks, the accountabilities and roles of the functions involved with enterprise risk management, the risk portfolio and the related actions implemented by our executive team;
|
•
|
Inform the Board on a periodic basis on the enterprise risk management system and on the Company’s most significant risks and how these are managed; and
|
•
|
Receive, as and when appropriate, reports from internal audit function on the results of risk management reviews and assessments.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
34
|
•
|
Seven of our ten Executive Committee members are women;
|
•
|
Members of the Executive Committee represent different ethnicities;
|
•
|
Approximately half of our employees are female and, among the total employee population, there are a number of ethnicities and backgrounds represented;
|
•
|
Alexion is one of only three companies in the S&P 500, and the only biotechnology company in the S&P 500, where a majority of senior executives are women (as reported by S&P Global);
|
•
|
Two most recent Board of Directors appointments were women; and
|
•
|
Alexion has adopted the "Rooney Rule" in connection with filling any vacant Board positions.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
35
|
|
CSR at Alexion encompasses environmental, social and governance topics that impact our business and our stakeholders. We have undertaken significant groundwork to identify and prioritize our most important CSR-related topics. From these efforts, we developed the Alexion CSR-STAR Platform as our structural framework, along with a series of corresponding aspirations and performance metrics.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
36
|
|
SERVE: Communities & Sustain Our Planet
We invest in our communities and shared planet in support of those who depend on us today and for generations that follow.
OUR COMMUNITIES:
•
8 HOURS: Of paid time off for Alexion employees introduced for qualified volunteer activities
OUR PLANET:
•
ZERO: Process waste-to-landfill status achieved enterprise-wide
|
|
TRANSFORM: Patient Lives
We urgently seek to understand patient journeys, find answers, and collaborate to deliver access to therapies that change lives.
•
In 2019, all new international patient support programs had patient organizations involved in their development, design and implementation.
|
|
ADVANCE: Our People and Our Company
We aspire to become the most engaging place to work, embracing diversity and governing and managing our business to return value to our stakeholders.
•
34-POINT improvement in the likelihood of employees recommending Alexion as a great company to work for
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
37
|
|
REDEFINE: What It Means To Live With A Rare Disease
We pioneered complement biology, spurring new treatments for devastating disorders. We work to advance healthcare through innovative diagnostics and proactive transparency.
•
In 2019, we formed an internal, cross-functional Transparency and Disclosure Committee to further our voluntary data sharing efforts from clinical studies.
|
|
ETHICS & COMPLIANCE: Our Foundation
We build trust when we make the right choices and act with integrity. Our unwavering commitment to ethics, quality and compliance improves our ability to serve patients and enhances our reputation and competitive advantage.
•
37 live anti-bribery/anti-corruption training workshops conducted around the world in 2018 and 2019
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
38
|
•
|
Understanding the moments that matter to patients and our employees
|
•
|
Engaging with our patient communities, to listen and learn from them and bring the patient voice into our daily work
|
•
|
Building the environment, processes, systems, and incentives for our employees to do and feel their best
|
•
|
Recognizing individual and team successes through reward and recognition programs
|
•
|
Investing in individual development and world-class leadership and innovation
|
•
|
Unlocking the power of insights and technology as innovation differentiators
|
•
|
Embracing and organizing for future opportunities and setting the example as leaders of change
|
•
|
Fostering a culture of belonging
|
•
|
Promoting a culture of high integrity through our updated Code of Conduct and compliance program that reaches our 3,000 talented colleagues across the globe
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
39
|
Executive Compensation
|
•
|
Ensuring that a greater proportion of total compensation is at-risk (cash and equity incentives) and ultimately linked to financial and operational performance and the execution of strategic initiatives: for 2019, 92% of total Chief Executive Officer compensation was at-risk.
|
•
|
Enhancing our program to ensure long-term and performance-based equity incentives are the primary component of overall pay. For 2019, equity incentives accounted for more than 80% of our CEO's compensation overall, with Performance Share Units, or PSUs, accounting for over 50% of our CEO's compensation.
|
•
|
Further increasing, for 2020, the transparency of long-term goals and performance linkage of these equity incentives (as well as further aligning equity compensation with shareholder returns), consistent with market best practices by:
|
◦
|
Adding goals related to product launch outcomes, which are disclosed in greater detail in the Compensation Discussion and Analysis, or CD&A, in addition to R&D goals,
|
◦
|
Strengthening the link between payouts and total shareholder return, or TSR, by capping the number of PSUs that may be earned if relative TSR (as explained in the CD&A in detail beginning on page 67) is below the median of our TSR peer group (regardless of corporate performance), and
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
40
|
◦
|
Reducing the maximum payouts of our PSUs from 300% to 200% of target.
|
•
|
Redesigning our CD&A to improve transparency (particularly with respect to the product launch goals component of PSUs) along with detailing the elements and features of our program that incorporate best practices while closely linking pay with performance.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
41
|
|
|
Name
|
Position
|
Hire Date
|
|
|
|
|
|
|
|
Named Executive Officers: Name, Position and Hire Date
|
|
Ludwig N. Hantson, Ph.D.
|
Chief Executive Officer
|
March 27, 2017
|
|
|
Aradhana Sarin, M.D.
|
Executive Vice President, Chief Financial Officer
|
November 13, 2017
|
|
|
|
Paul J. Clancy1
|
Executive Vice President, Senior Advisor and Former Chief Financial Officer
|
July 10, 2017
|
|
|
|
Brian M. Goff
|
Executive Vice President, Chief Commercial and Global Operations Officer
|
June 1, 2017
|
|
|
|
Anne-Marie Law
|
Executive Vice President, Chief Human Experience Officer
|
June 5, 2017
|
|
|
|
John Orloff
|
Executive Vice President, Head of Research and Development
|
June 5, 2017
|
|
CD&A Table of Contents
|
Executive Summary
|
page 43
|
Executive Compensation Framework
|
page 52
|
|
2019 Compensation Components and Key Compensation Actions
|
page 55
|
|
Compensation Governance
|
page 69
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
42
|
•
|
Pay-for-Performance: Our program is designed to reward executives for actions that create short-term and long-term, sustainable shareholder value, with a strong focus on performance-based compensation, including PSUs.
|
•
|
Alignment: Our program strives to increase the alignment of executives’ interests with those of our shareholders through the use of stock-based compensation and stock ownership guidelines.
|
•
|
Retention: Our program aims to attract, retain and incentivize the best talent in the industry in order to ensure executive stability and continuity that we believe is necessary for consistent execution of our long-term strategy, which is particularly critical given our industry and the lifecycle of our pipeline. As we re-build the pipeline with assets that are at various stages of development, including pre-clinical, early stage and later stage, continuity at the executive level is critical to advancing these products as it can take product candidates years to advance through identification and development to commercialization.
|
•
|
Competitive Pay: The resulting overall compensation program is significantly at-risk, based on market best practices, yet competitive with other companies who aggressively compete with us for top talent both on an industry and geographical bases. We believe that our ability to attract and retain top talent at all levels of the organization is a source of competitive advantage for us as Alexion advances into new platforms, geographies, technologies, indications and competitive spaces.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
43
|
|
Current Incentive Design
|
Enhancements from Prior Years
|
|
|
|
Annual Incentives Performance Link
|
Annual bonus payouts are based on performance against objective, pre-established financial and strategic goals; Over 80% of payouts tied to the achievement of financial goals given some of our strategic goals have financial related objectives
|
Transitioned from 100% subjective goals in 2016
|
Annual Incentives Maximum Payout
|
Payout capped at 200% of target
|
Reduced from maximum of 300% of target in 2016
|
LTI Mix
|
PSUs comprise 65% of LTI awards
|
Increased from 25% in 2016, and 50% in 2017
|
PSU Maximum Payout
|
New for 2020: Payout capped at 200% of target
|
Reduced from 900% in 2016, 350% in 2017, and 300% in 2018 and 2019
|
PSU Performance Period
|
3-year performance period (3-year goals and cliff vesting)
|
Changed from 1-year performance goals with 3-year ratable vesting in 2016 and 2017
|
PSU Goal Transparency
|
New for 2020: Linked payout to achievement of product launch and revenue goals
|
Changed from goals relating to the achievement of R&D and clinical trial milestones and additions to our pipeline in prior years
|
PSU TSR Payout Cap
|
New for 2020: Relative TSR component limits overall payout if not above peer median
|
TSR modifier impacted operational payout to increase or decrease the payout if above or below top or bottom quartile of peers in 2018 and 2019
|
•
|
Incentive performance goals encompass financial, operational, strategic, and shareholder return metrics ensuring executive focus on broad-based strategic execution and links payouts realized by executives to strong financial performance and shareholder value creation;
|
•
|
Annual cash incentive payout based 100% on established goals that we believe furthers execution of the Company’s strategy and advances financial performance;
|
•
|
2019 annual cash incentive financial targets were set significantly higher than actual 2018 performance;
|
•
|
PSUs comprise 65% of LTI awards, and over 50% of CEO target total direct compensation (total direct compensation consists of base salary and cash and equity incentives);
|
•
|
Inclusion of TSR metric in PSUs ensures that the number of shares of common stock issued to the executive is directly aligned with shareholder value creation during the term of the PSU; and
|
•
|
RSUs vest on a ratable basis annually over four years to serve our talent retention objectives and further align executives’ interests with those of our shareholders.
|
•
|
2019 financial performance was outstanding: Total revenues for 2019 were $4,991 million, a 21% increase compared to 2018. On a GAAP1 basis, diluted earnings per share was $10.70, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, compared to $0.35 in the prior year, inclusive of $1,183 million of expense related to the value of the in-process research and development assets acquired in 2018. Non-GAAP1 diluted
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
44
|
•
|
Performance goals that underpinned 2019's annual incentives were significantly higher than the Company’s 2018 actual performance. These 2019 performance incentive targets, and the resulting pay-outs, were driven, in part, by (i) ULTOMIRIS facilitated patient conversion performance, with ULTOMIRIS being established as the standard of care for PNH in our top three markets (US, Germany and Japan) and (ii) the steps taken during 2019 to rebuild and expand our pipeline to include 18 development programs in 9 assets.
|
•
|
Despite our 2019 performance, the CEO’s annual cash incentive earned was $2.43 million, a 16% decline as compared to 2018, which was due in part to the fact that the corporate performance and individual goals for 2019 had been set at a higher and more demanding threshold in comparison to the prior year, so even the very solid 2019 performance (which was, by many metrics, Alexion's best year) was measured against a much higher bar that was set by the Committee than 2018. However, since the executive team took control in 2017, they have been successful, and have not turned their focus from expanding and diversifying our pipeline which can take years to translate into returns in financial performance and increased shareholder value.
|
•
|
While we believe our current stock price undervalues the company today and our 2019 Annual Incentive Plan paid out above target, our executives continue to remain aligned with shareholders as equity constitutes the largest component of their total compensation and the 2017 TSR PSUs (that were scheduled to vest in early 2020) were forfeited in entirety given our TSR results. The Committee continues to emphasize the importance of shareholder-linked equity compensation by including a payout cap in the 2020 PSU program for TSR performance below the median of the TSR peer group.
|
•
|
We continued to focus on at-risk pay elements, with over 92% of the CEO’s total compensation being at-risk.
|
•
|
PSUs linked to the achievement of 3-year financial and operational goals, as well as our relative TSR and R&D milestones, represented approximately 60% of total incentives (annual cash incentives and LTI) for our executives for 2019, as well as over 50% of total direct compensation for the CEO for 2019.
|
•
|
We continue to enhance our executive compensation program to further strengthen the link between pay and performance and to incentivize our executives to focus on long-term shareholder value creation.
|
•
|
We continued to engage with shareholders and stakeholders and continue to receive their feedback and general support on our evolving compensation programs.
|
•
|
For 2020, we have capped the maximum payout for PSUs at 200% of target. We have also increased transparency of the PSU goals and replaced the R&D clinical trial milestones with product launch goals. Additionally, we have modified the relative TSR component to cap the number of shares of common stock that will be issued upon vesting (regardless of corporate performance) if relative TSR is not at least at peer median. With our newly implemented relative TSR cap (which was also refer to as a TSR "gate") we are more closely aligning our executives PSU payout to shareholder value creation.
|
•
|
We continue to emphasize variable and performance-based incentives which, for the CEO, comprise over 90% of total direct compensation with PSUs accounting for over 50% of total direct compensation.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
45
|
•
|
We have not only increased the at-risk focus of total compensation, but (consistent with the past three years) set rigorous goals for the metrics underpinning those incentives (see "Year Over Year Financial Performance Targets & Results" on page 59).
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
46
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
47
|
Lead with ULTOMIRIS® (ravulizumab-cwvz) in PNH; Deliver successful launch in aHUS
|
ü
|
Established ULTOMIRIS as the market leader in PNH within the first year of launch; launched ULTOMIRIS in aHUS
|
ü
|
Best-in-class ULTOMIRIS facilitated patient PNH conversion in key markets of US, Germany and Japan
|
|
|
|
|
Accelerate neurology portfolio
|
ü
|
SOLIRIS continued to gain strong traction in gMG and NMOSD
|
ü
|
Neurology has become largest franchise in the U.S. by patient volume
|
|
ü
|
Ended 2019 with 1,885 patients on treatment with SOLIRIS for gMG and NMOSD in the U.S.
|
|
|
|
|
Grow Metabolics Portfolio
|
ü
|
Continued work to expand access for HPP and LAL-D patients
|
ü
|
Metabolic sales grew 24% year over year, driven by increase in volume
|
|
|
|
|
Execute and Expand Pipeline
|
ü
|
Furthered diversification beyond C5 with Achillion acquisition - Factor D provides opportunity to pursue development in a broad range of indications - and six additional business development transactions
|
ü
|
Expanded pipeline with plans to advance ULTOMIRIS into 6 additional indications across neurology and nephrology
|
|
ü
|
Robust pipeline with potential for 10 launches by end of 2023
|
|
|
|
|
Delivered on Financial Ambitions
|
ü
|
Drove strong total revenues of $4,991 million in 2019, 21% increase compared to 2018
|
ü
|
Delivered GAAP* diluted EPS of $10.70 in 2019 compared to $0.35 in the prior year. Non-GAAP* diluted EPS for 2019 was $10.53, a 33% increase versus the prior year
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
48
|
|
Revenue growth year over year
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
49
|
|
Met with or Contacted
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
50
|
•
|
generic pharmaceutical companies (where results are not driven by innovation and expanding product pipelines with new technologies, where products have different life cycles and less complex reimbursement and access strategies and where a much smaller percentage of revenue is dedicated to research and development),
|
•
|
medical device companies (not in the drug development space),
|
•
|
an animal health organization (that operates under an entirely different model and regulatory regime), and
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
51
|
•
|
a contract research organization (a service provider, not a research and development driven developer of proprietary medicines, not in the pharmaceutical development or pharmaceutical product sales and distribution space).
|
•
|
Enhance alignment with our pay-for-performance philosophy
|
•
|
Strengthen the link between executive and shareholder interests
|
•
|
Incorporate good corporate governance practices
|
•
|
Align with competitive and best market practices
|
•
|
Reflect input received from shareholders and proxy advisory firms
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
52
|
|
2016
|
|
|
|
|
|
Change-in-Control Enhancements
|
|
|
|
Eliminated:
Single-trigger vesting on a change-in-control
Section 280G gross-up entitlements
|
|
|
|
|
|
|
|
2017
|
|
|
|
|
|
Long-Term Incentive Mix
|
|
|
|
Reduced Stock Options from 50% to 20%
Increased RSUs from 25% to 30%
Increased PSUs from 25% to 50%
|
|
Annual Cash Incentive Plan
|
|
|
|
Transitioned bonus payouts from 100% based on subjective performance to being based on performance against pre-established goals (50% financial and 50% strategic)
Reduced maximum payout from 300% to 200%
|
|
Performance Share Unit Plan
|
|
|
|
Reduced maximum payout from ~900% to 350%
|
|
|
|
|
|
|
|
2018
|
|
|
|
|
|
Long-Term Incentive Mix
|
|
|
|
Eliminated Stock Options
Increased RSUs from 30% to 35%
Increased PSUs from 50% to 65%
|
|
Annual Cash Incentive Plan
|
|
|
|
Increased weighting of financial goals from 50% to 65%; bringing total potential pay-out tied to financial goals to over 80% given some strategic goals have financial objectives
|
|
Performance Share Unit Plan
|
|
|
|
Reduced maximum payout from 350% to 300%
Shifted from a 1-year performance period with 3-year ratable vesting to a 3-year performance period with cliff vesting
|
|
|
|
|
|
|
|
2019
|
|
|
|
|
|
Performance Share Unit Plan
|
|
|
|
Increased weighting of Revenue goal from 40% to 60% and reduced weighting of Operating Margin goal from 60% to 40%
Shifted from applying the rTSR modifier based on a sliding scale to a "cliff" approach with binary outcomes for performance below or above the 25th and 75th percentiles
|
|
|
|
|
|
|
|
2020
|
|
|
|
|
|
Performance Share Unit Plan
|
|
|
|
Reduced maximum payout from 300% to 200%
Increased weighting of Revenue goal from 60% to 70%
Removed Operating Margin as a goal and replaced with R&D launch goals, weighted at 30%
Introduced a relative TSR cap to limit payouts if at or below peer median
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
53
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
54
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
55
|
Compensation Component
|
Link to Business and Talent Strategies
|
2019 Compensation Actions
|
|
|
|
Base Salary
|
Provide competitive, fixed, cash compensation to attract and retain top talent and recognize sustained performance, job scope and experience
|
Annual Base Salaries established at the beginning of the year are:
Reviewed annually against survey and peer market data
Changes are made based on position relative to market and performance
2019 increases were based on market positioning and reflective of expanded roles and promotions
|
Annual Cash Incentive Compensation
|
Motivate executives to achieve rigorous annual financial and strategic goals that support our short- and long-term objectives
|
Annual Financial and Strategic goals established at the beginning of 2019 include:
Financial (65%):
Revenue
Non-GAAP Operating Margin
Non-GAAP EPS
Strategic (35%):
Creating Value
Rebuilding Clinical Stage Pipeline
Most Rewarding Company to Work For
Performance against these goals is assessed after the end of the fiscal year by the Committee
Overall, our 2019 performance versus our goals exceeded targets and our corporate achievement was 162% of target
Bonus payouts ranged from 162% to 178% of target recognizing the strong corporate results and superior performance of certain members of our leadership team
|
LTI Compensation
|
Motivate and reward executives for exceptional execution of long-term financial and strategic objectives, while providing a direct link to the creation of sustainable shareholder value and execution of our strategic business plan; align the interests of executives with those of our shareholders
|
Annual LTI awards granted in February of 2019 include:
PSUs (65%):
3-year performance period with "cliff" vesting upon certification by the Committee
Dependent on the achievement of Revenue and non-GAAP Operating Margin financial goals
Reflects goals that the Committee has identified as key indicators of Company performance and creation of shareholder value
Provides an opportunity for additional PSUs to be earned based on long-term value creation through R&D milestones
Shares ultimately earned can be increased or decreased based on our relative total shareholder return performance
RSUs (35%):
4-year ratable vesting
Provide focus on stock price growth and serve our talent retention objectives
2017 Earned TSR PSUs:
Based on Alexion's 3-year relative TSR results, the Committee certified a payout of 0% resulting in the PSUs being canceled
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
56
|
•
|
Merit/Market Adjustments: Dr. Hantson, Mr. Clancy, Mr. Goff, and Dr. Orloff each received a merit increase in 2019 and Mr. Goff and Dr. Orloff received further adjustments to better align their salaries with market.
|
•
|
Expanded Role: Ms. Law's increase reflects additional responsibility in her role to include leading patient engagement and advocacy in addition to the employee experience.
|
•
|
Promotions: Dr. Sarin's increases reflected two role changes during 2019. Her promotion from SVP to EVP in February 2019, with an expanded scope to include Chief of Staff to CEO responsibilities (increase to $600,000), and in September 2019, Dr. Sarin's promotion to CFO (increase to $800,000).
|
2019 Base Salary Changes1
|
CEO
|
2018 Base Salary
|
2019 Base Salary
|
% Change
|
Ludwig Hantson
|
$1,200,000
|
$1,250,000
|
4%
|
2019 Base Salary Changes1
|
All Other Named Executive Officers
|
2018 Base Salary
|
2019 Base Salary
|
% Change
|
Aradhana Sarin2
|
$517,500
|
$800,000
|
55%
|
|
Paul Clancy
|
$900,000
|
$927,000
|
3%
|
|
Brian Goff
|
$695,250
|
$740,000
|
6%
|
|
Anne-Marie Law
|
$650,000
|
$695,000
|
7%
|
|
John Orloff
|
$695,250
|
$770,000
|
11%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
57
|
•
|
Market Adjustments: Dr. Hantson and Dr. Orloff each received increases to better align their salaries with market.
|
•
|
Expanded Roles: Mr. Goff became our Chief Commercial & Global Operations Officer that now includes responsibility for driving continued long-term growth and aligning our commercial and operations strategy to serve more patients and families with rare and devastating diseases. Ms. Law became our Chief Human Experience Officer to reflect her expanded role that now includes the technology function to evolve our digital employee and patient experiences.
|
2020 Base Salary Changes
|
CEO
|
2019 Base Salary
|
2020 Base Salary
|
% Change
|
Ludwig Hantson
|
$1,250,000
|
$1,300,000
|
4%
|
2020 Base Salary Changes
|
All Other Named Executive Officers
|
2019 Base Salary
|
2020 Base Salary
|
% Change
|
Aradhana Sarin
|
$800,000
|
$800,000
|
0%
|
|
Paul Clancy
|
$927,000
|
$927,000
|
0%
|
|
Brian Goff
|
$740,000
|
$799,200
|
8%
|
|
Anne-Marie Law
|
$695,000
|
$729,750
|
5%
|
|
John Orloff
|
$770,000
|
$831,600
|
8%
|
2019 Annual Incentive Targets (% of Base Salary)
|
CEO
|
2019 Target
|
2018 Target
|
Ludwig Hantson
|
120%
|
120%
|
2019 Annual Incentive Targets (% of Base Salary)
|
All Other Named Executive Officers
|
2019 Target
|
2018 Target
|
Aradhana Sarin1
|
70%
|
45%
|
|
Paul Clancy
|
70%
|
70%
|
|
Brian Goff
|
70%
|
70%
|
|
Anne-Marie Law
|
70%
|
70%
|
|
John Orloff
|
70%
|
70%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
58
|
•
|
No annual cash incentive is payable if the threshold performance goals are not achieved
|
•
|
A maximum of 200% of target is payable for achieving the highest level of performance
|
•
|
Individual performance is a modifier, with the potential to increase or decrease an NEO's cash incentive (but not in excess of 200% of target)
|
Eligible Earnings
|
X
|
Target %
|
X
|
Corporate Multiplier (Financial & Strategic Weighted Funding)
|
X
|
Individual Performance Multiplier
|
=
|
Max Payout Capped at 200%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
59
|
|
Target Increases over Prior Year Actual
|
|
|
2018 Target vs. 2017 Actual
|
2019 Target vs. 2018 Actual
|
|
|
|
Revenue
|
12%
|
10%
|
Non-GAAP EPS
|
17%
|
14%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
60
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
61
|
Funding for Financial Performance = 109%
|
||||||
Funding for Strategic Performance = 53%
|
||||||
2019 Total Performance Funding = 162%
|
•
|
Executing on our redefined strategy and delivering on our key objectives for 2019, which in many cases surpassed our goals
|
•
|
Establishing ULTOMIRIS as the market leader in PNH in US, Germany and Japan
|
•
|
The strong progression of ULTOMIRIS’ aHUS conversion in the US
|
•
|
Neurology becoming our largest franchise in the US by patient volume with the continued growth of SOLIRIS in gMG and the launch in NMOSD
|
•
|
Our progress towards transforming and advancing our development portfolio, including delivery of three positive Phase 3 programs, four successful launches, entered into seven business development deals and the initiation of multiple additional clinical programs with our medicines
|
•
|
Entering into an agreement to acquire Achillion (which was closed in January 2020), which represents an important step in diversifying our business beyond C5 and giving us the opportunity to develop Factor D assets
|
•
|
Our double-digit revenue growth in 2019
|
•
|
Continued financial growth, including double-digit revenue growth driven by strength in our neurology franchise, continued growth in our complement and metabolic products and the ULTOMIRIS launch
|
•
|
Entering into seven business development deals, which were designed to further diversify our pipeline to pursue development in a broader range of indications and beyond C5 complement inhibitors
|
•
|
Establishing ULTOMIRIS as the market leader in PNH in US, Germany and Japan
|
•
|
The strong progression of ULTOMIRIS’ aHUS conversion in the US
|
•
|
Neurology becoming our largest franchise in the US by patient volume with the continued growth of SOLIRIS in gMG and the launch in NMOSD
|
•
|
Strong continued growth of metabolic sales
|
•
|
Continued expansion of a global sales team and program that can work towards expanding patient access
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
62
|
•
|
Recruiting and onboarding of over 800 colleagues to meet the company's growth ambitions
|
•
|
Forming a new Patient Experience function to elevate patient centricity and build global patient advocacy capabilities
|
•
|
Developing Alexion's digital strategy and creating the foundation for digital patient and employee experiences through the launch of a patient insights portal and employee engagement platform
|
•
|
Steering a patient-centric ALS protocol development and trial design by engaging with the patient and KOL (Key Opinion Leader) community
|
•
|
Achieving multiple regulatory submissions and approvals ahead of schedule
|
•
|
Preparing Alexion for 18 clinical-stage development programs in 9 assets for 2020
|
2019 AIP Payout
|
CEO
|
2019 Target
|
Annual Cash Incentive Paid
|
Corporate Multiplier
|
Individual Performance Multiplier
|
% of Target
|
Ludwig Hantson
|
$1,500,000
|
$2,430,000
|
162%
|
100%
|
162%
|
2019 AIP Payout
|
All Other Named Executive Officers
|
2019 Target
|
Annual Cash Incentive Paid
|
Corporate Multiplier
|
Individual Performance Multiplier
|
% of Target
|
Aradhana Sarin1
|
$456,235
|
$813,011
|
162%
|
110%
|
178%
|
|
Paul Clancy
|
$648,900
|
$1,051,218
|
162%
|
100%
|
162%
|
|
Brian Goff
|
$518,000
|
$923,076
|
162%
|
110%
|
178%
|
|
Anne-Marie Law
|
$486,500
|
$788,130
|
162%
|
100%
|
162%
|
|
John Orloff
|
$539,000
|
$960,498
|
162%
|
110%
|
178%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
63
|
2020 Annual Incentive Targets (% of Base Salary)
|
CEO
|
2020 Target
|
2019 Target
|
Ludwig Hantson
|
135%
|
120%
|
2020 Annual Incentive Targets (% of Base Salary)
|
All Other Named Executive Officers
|
2020 Target
|
2019 Target
|
Aradhana Sarin
|
70%
|
70%
|
|
Brian Goff
|
70%
|
70%
|
|
Anne-Marie Law
|
70%
|
70%
|
|
John Orloff
|
70%
|
70%
|
•
|
Peer group and market data;
|
•
|
The individual's historic contributions and potential contributions to Alexion's growth and financial results;
|
•
|
The value of proposed awards;
|
•
|
Corporate performance; and
|
•
|
The individual's level of responsibility within Alexion.
|
Performance Share Units 65%
|
+
|
Restricted Stock Units 35%
|
=
|
Long Term Incentive Award
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
64
|
|
|
2019
|
2018
|
||||
LTI Awards
|
CEO
|
Proposed Equity Value1
|
Number of RSUs
|
Number of PSUs
(At Target)
|
Proposed Equity Value1
|
Number of RSUs
|
Number of PSUs
(At Target)
|
Ludwig Hantson
|
$12,625,000
|
37,198
|
69,082
|
$12,000,000
|
35,760
|
66,411
|
|
|
2019
|
2018
|
||||
LTI Awards
|
All Other Named Executive Officers
|
Proposed Equity Value1
|
Number of RSUs
|
Number of PSUs
(At Target)
|
Proposed Equity Value1
|
Number of RSUs
|
Number of PSUs
(At Target)
|
Aradhana Sarin2
|
$2,800,000
|
8,250
|
15,321
|
-
|
-
|
-
|
|
Paul Clancy
|
$3,200,000
|
9,428
|
17,510
|
$3,200,000
|
9,536
|
17,710
|
|
Brian Goff
|
$3,200,000
|
9,428
|
17,510
|
$3,000,000
|
8,940
|
16,603
|
|
Anne-Marie Law
|
$3,000,000
|
8,839
|
16,416
|
$2,800,000
|
8,344
|
15,496
|
|
John Orloff
|
$3,200,000
|
9,428
|
17,510
|
$3,000,000
|
8,940
|
16,603
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
65
|
2019 PSU Incentive Components
|
||
Operational PSUs
|
Cumulative Revenue CAGR (60% weighting)
|
|
Operating Margin (40% weighting)
|
||
* 0 to 200% of payout
|
||
|
X
|
|
Relative TSR Modifier
|
Relative TSR (+/- 20%)
|
|
* Up to +/- 20% of the earned Operational PSUs
* If Operational PSUs earned at maximum, adjustment for TSR can be up to +/- 40% (200% x 20%)
|
||
|
+
|
|
R&D PSUs
|
R&D Milestones (+60%)
|
|
* Up to an additional 60% of payout
|
||
|
|
|
Maximum = 300%
|
||
Example for Maximum Payout:
|
||||||||||
|
Operational PSUs
|
|
|
rTSR Modifier
|
|
R&D Milestones
|
|
Payout
|
||
(
|
Cumulative Revenue CAGR
|
|
Operating Margin
|
)
|
X
|
+
|
=
|
|||
(200% x 60%)
|
+
|
(200% x 40%)
|
20%
|
60%
|
300%
|
|||||
200%
|
40%
|
60%
|
•
|
Change from 2018: Increased the weighting on revenue from 40% to 60% to focus on top line growth
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
66
|
•
|
Up to a 40% increase in the number of earned operational PSUs if our rTSR is above the 75th percentile of the TSR Peer Group
|
•
|
Up to a 40% decrease in the number of earned operational PSUs if our rTSR is below the 25th percentile of the TSR Peer Group
|
◦
|
The maximum adjustment of +/- 40% will only apply if the Operational PSUs are earned at maximum (200% x 20% = 40%)
|
•
|
No modification to the Operational PSUs if performance is between the 25th and 75th percentiles
|
•
|
Change from 2018: Shifted from applying a modifier based on a sliding scale approach (i.e., an increase or decrease for each 1% that our rTSR is above or below the 75th or 25th percentiles, respectively) to a cliff approach to enhance the impact of TSR results and create further shareholder alignment
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
67
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
68
|
Alexion TSR Performance vs. Peer Group Median
|
Payout as a
% of Target
|
> Median + 75%
|
250%
|
For every 1% achieved above median
|
2%
|
Alexion TSR performance equals the median
|
100%
|
For every 1% decline below median, up to - 50%
|
-2%
|
< Median - 50%
|
No payout
|
Results
|
|
Alexion TSR
|
-17%
|
Index Median TSR
|
57%
|
Underperformance
|
-74%
|
PSUs Earned
|
0%
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
69
|
Named Executive Officer
|
2017 Target Number of TSR PSUs
|
Achievement Percentage
|
2017 Earned Number of TSR PSUs
|
Ludwig N. Hantson
|
9,575
|
0%
|
0
|
Aradhana Sarin1
|
N/A
|
||
Paul J. Clancy
|
4,848
|
0%
|
0
|
Brian M. Goff
|
1,598
|
0%
|
0
|
Anne-Marie Law1
|
N/A
|
||
John Orloff1
|
N/A
|
•
|
Its review of corporate results against financial and strategic corporate objectives that are established early in the year, assigning a performance score as a percentage of target
|
•
|
An annual benchmarking exercise to obtain competitive market information and compare each executive's compensation to that of individuals in similar positions at Alexion's selected peer group of companies
|
•
|
The CEO's assessment of the performance of the executives measured against their objectives
|
•
|
The CEO's compensation recommendations for the executives
|
•
|
The Committee's assessment of the CEO's performance
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
70
|
Compensation Levels
|
As an input to determine base salary, annual cash incentives, grant date value of long-term incentive awards, and total direct compensation.
|
Program Design
|
As an input for designing our executive compensation programs.
|
Pay-for-Performance
|
To assess whether Alexion’s executive compensation programs are aligned with Company performance.
|
Aggregate Equity Usage
|
To assess incentive plan burn rate, overhang and equity expense.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
71
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
72
|
2019 Peer Group
|
AbbVie Inc.
|
BioMarin Pharmaceutical, Inc.
|
Regeneron Pharmaceuticals, Inc.
|
Alkermes plc
|
Celgene Corporation
|
Seattle Genetics, Inc.
|
|
Allergan plc
|
Gilead Sciences, Inc.
|
Shire plc
|
|
Amgen Inc.
|
Incyte Corporation
|
United Therapeutics Corporation
|
|
Biogen Inc.
|
Jazz Pharmaceuticals plc
|
Vertex Pharmaceuticals, Inc.
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
Revenue
|
|
|
|
45th %ile
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-US Revenue
|
|
|
|
|
52nd %ile
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market Cap (as of 12/31/19)
|
|
38th %ile
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio: Market Cap to Revenue
|
|
|
|
|
|
|
66th %ile
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Employees
|
|
41st %ile
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CEO's 2019 Target Total Direct Compensation
|
|
46th %ile
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
73
|
Officer Level
|
Guideline Multiple of Base Salary or Annual Retainer
|
Chief Executive Officer
|
6x
|
Executive Vice Presidents and Senior Vice Presidents reporting to the CEO
|
3x
|
Other Senior Vice Presidents
|
1x
|
Directors
|
5x
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
74
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
75
|
Summary Compensation Table
|
Name and Principal Position
|
Year
|
Salary
($)
|
Bonus ($) (5)
|
Stock
Awards ($) (6) |
Option Awards
($) (6)
|
Non-Equity Incentive Plan Compen-sation
($)(7)
|
All Other Compen-sation
($) (8)
|
Total
($)
|
Ludwig Hantson (1)
|
2019
|
1,250,000
|
—
|
15,243,634
|
—
|
2,430,000
|
24,350
|
18,947,984
|
Chief Executive Officer
|
2018
|
1,200,000
|
—
|
12,385,168
|
—
|
2,880,000
|
25,082
|
16,490,250
|
2017
|
900,000
|
—
|
9,618,758
|
2,282,881
|
2,275,000
|
233,428
|
15,310,067
|
|
Aradhana Sarin (2)
|
2019
|
651,764
|
—
|
3,380,763
|
—
|
813,011
|
31,604
|
4,877,142
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paul Clancy (3)
|
2019
|
927,000
|
—
|
3,863,694
|
—
|
1,051,218
|
23,832
|
5,865,744
|
Executive Vice President, Senior Advisor and Former Chief Financial Officer
|
2018
|
900,000
|
—
|
3,302,761
|
—
|
1,260,000
|
23,752
|
5,486,513
|
2017
|
415,385
|
500,000
|
8,799,954
|
1,220,082
|
473,620
|
2,262
|
11,411,303
|
|
Brian Goff (4)
|
2019
|
740,000
|
—
|
3,863,694
|
—
|
923,076
|
20,240
|
5,547,010
|
Executive Vice President, Chief Commercial and Global Operations Officer
|
2018
|
695,250
|
—
|
3,096,323
|
—
|
973,350
|
111,873
|
4,876,796
|
2017
|
381,634
|
100,000
|
2,390,026
|
732,899
|
434,380
|
58,787
|
4,097,726
|
|
Anne-Marie Law (4)
|
2019
|
695,000
|
—
|
3,622,303
|
—
|
788,130
|
33,528
|
5,138,961
|
Executive Vice President, Chief Human Experience Officer
|
2018
|
650,000
|
—
|
2,889,885
|
—
|
910,000
|
846,604
|
5,296,489
|
2017
|
362,500
|
200,000
|
2,300,015
|
—
|
410,472
|
68,710
|
3,341,697
|
|
John Orloff (4)
|
2019
|
770,000
|
—
|
3,863,694
|
—
|
960,498
|
32,550
|
5,626,742
|
Executive Vice President, Head of Research and Development
|
2018
|
695,250
|
—
|
3,096,323
|
—
|
973,350
|
98,679
|
4,863,602
|
2017
|
376,442
|
200,000
|
2,499,995
|
—
|
472,500
|
80,351
|
3,629,288
|
(1)
|
Dr. Hantson joined Alexion in March 2017. The amount of salary reported for 2017 reflects that Dr. Hantson's 2017 annual salary was pro-rated to reflect that he was employed for three-fourths of the year for 2017.
|
(2)
|
Dr. Sarin joined the Company in November 2017 as Senior Vice President, Business Development and Corporate Strategy and from February 2019 to October 2019, she has served as Executive Vice President, Chief Strategy and Business Officer and Chief of Staff to the CEO. On September 17, 2019, the Board of Directors appointed Dr. Sarin as Executive Vice President and Chief Financial Officer, effective in October 2019. Dr. Sarin's annual base salary for 2019 as Chief Strategy and Business Officer and Chief of Staff to the CEO was $600,000, retroactive to January 2019, until her appointment as Executive Vice President and Chief Financial Officer, at which time her annual base salary was increased to $800,000, commensurate with her new position. No amounts are reported for Dr. Sarin for 2017 or 2018 because she was not a named executive officer for either of those years.
|
(3)
|
Mr. Clancy joined Alexion in July 2017. The amount of salary and non-equity incentive plan compensation reported for 2017 reflects that Mr. Clancy's annual base salary and annual bonus were both pro-rated to reflect that he was employed for only a portion of 2017. In September 2019, Mr. Clancy notified the Company that he will not renew his employment agreement with the Company at its scheduled expiration date of July 10, 2020. Mr. Clancy served as the Company's Executive Vice President and Chief Financial Officer through October 2019, at which point he transitioned to the role of Executive Vice President, Senior Advisor. Mr. Clancy is expected to continue to serve in this role through July 11, 2020 to, among other things, assist in the transition of his former duties to the new Chief Financial Officer. Mr. Clancy will forfeit his 2018 and 2019 PSUs and all of his then-unvested RSUs as of the date of his departure.
|
(4)
|
Mr. Goff, Ms. Law and Dr. Orloff joined Alexion in June 2017. The amount of salary and non-equity incentive plan compensation reported for them for 2017 reflects that their annual base salary and annual bonuses were pro-rated to reflect their employment for only a portion of 2017.
|
(5)
|
Amounts represent sign-on bonuses for Mr. Clancy, Mr. Goff, Dr. Orloff, and Ms. Law.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
76
|
(6)
|
Amounts represent the grant date fair value of stock awards and option awards granted to the named executive officer in each of 2019, 2018, and 2017 (where applicable), calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 ("FASB ASC Topic 718"), disregarding the effect of estimated forfeitures. See Notes 1 and 13 to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 for details as to the assumptions used to determine the fair value of the equity awards granted in 2019. See our audited consolidated financial statements in our Annual Reports on Form 10-K for the years ended December 31, 2018 and 2017 for details as to the assumptions used to determine the fair value of the awards granted in 2018 and 2017, respectively. The amount reported in the "Stock Awards" column include the grant date fair value of RSUs and PSUs, the terms of which are more fully discussed in the Compensation Discussion and Analysis above. For PSUs, the amounts represent the grant date fair value based on the probable outcome of the performance conditions at the grant date. For 2019, the grant date fair value of PSUs was $10,209,629 for Dr. Hantson, $2,264,291 for Dr. Sarin, $2,587,803 for Mr. Clancy, Mr. Goff and Dr. Orloff, and $2,426,121 for Ms. Law. The grant date fair value of these PSUs, if the highest level of performance conditions were achieved, is $30,628,886 for Dr. Hantson, $7,763,409 for Mr. Clancy, Mr. Goff and Dr. Orloff, $6,792,872 for Dr. Sarin and $7,278,362 for Ms. Law. Mr. Clancy's 2018 and 2019 PSUs will be forfeited upon his departure in July 2020.
|
(7)
|
Amounts represent the annual incentive bonus earned by each of the NEOs for services performed in 2019, 2018, and 2017 (where applicable). The annual incentive bonuses were paid in February or March of the calendar year following the year to which the bonus relates (e.g., the 2019 annual incentive bonus was paid in March 2020).
|
(8)
|
The amounts within the All Other Compensation column for 2019 are as follows:
|
Executive Officer
|
Company Retirement Contributions
($) (9)
|
Non-Qualified Deferred Compensation Match
($)
|
Other
($) (10)
|
Total
|
Ludwig Hantson
|
16,800
|
—
|
7,550
|
24,350
|
Aradhana Sarin
|
16,800
|
2,200
|
12,604
|
31,604
|
Paul Clancy
|
16,800
|
—
|
7,032
|
23,832
|
Brian Goff
|
16,800
|
—
|
3,440
|
20,240
|
Anne-Marie Law
|
16,800
|
8,200
|
8,528
|
33,528
|
John Orloff
|
16,800
|
8,200
|
7,550
|
32,550
|
(9)
|
Amounts represent employer matching contributions to the Alexion 401(K) plan related to employee 2019 contributions.
|
(10)
|
Amounts in this column for fiscal year 2019 include relocation benefits and related tax gross up benefits, commuter and parking benefits and executive annual physical costs. Excluded from such reported amounts for both Ms. Law and Dr. Orloff are $64,000 of costs repaid by the employees back to the Company for excess housing stipend expenses provided for in 2018 under the Company's relocation policy.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
77
|
Grants Of Plan-Based Awards In Fiscal 2019
|
|
|
|
Estimated Future Payouts Under Non-Equity Incentive Plan Awards
|
Estimated Future Payouts Under Equity Incentive Plan Awards
|
All Other Stock Awards:
|
All Other Option Awards:
|
|
|
||
Name
|
Grant Date
|
|
Target
($)
|
Maximum ($)
|
Target
(#)
|
Maximum (#)
|
Number of shares of stock or units
(#)
|
Number of Securities Underlying Options (#)
|
Exercise or Base Price of Option Awards ($/Sh)
|
Grant Date Fair Value of Stock and Option Awards
($) (4)
|
Ludwig Hantson
|
2/28/19
|
(1)
|
1,500,000
|
3,000,000
|
—
|
—
|
—
|
—
|
—
|
—
|
2/28/19
|
(2)
|
—
|
—
|
—
|
—
|
37,198
|
—
|
—
|
5,034,005
|
|
|
2/28/19
|
(3)
|
—
|
—
|
69,082
|
207,246
|
—
|
—
|
—
|
10,209,629
|
Aradhana Sarin
|
2/28/19
|
(1)
|
456,235
|
912,470
|
—
|
—
|
—
|
—
|
—
|
—
|
2/28/19
|
(2)
|
—
|
—
|
—
|
—
|
8,250
|
—
|
—
|
1,116,473
|
|
|
2/28/19
|
(3)
|
—
|
—
|
15,321
|
45,963
|
—
|
—
|
—
|
2,264,291
|
Paul Clancy
|
2/28/19
|
(1)
|
648,900
|
1,297,800
|
—
|
—
|
—
|
—
|
—
|
—
|
2/28/19
|
(2) (5)
|
—
|
—
|
—
|
—
|
9,428
|
—
|
—
|
1,275,891
|
|
|
2/28/19
|
(3) (5)
|
—
|
—
|
17,510
|
52,530
|
—
|
—
|
—
|
2,587,803
|
Brian Goff
|
2/28/19
|
(1)
|
518,000
|
1,036,000
|
—
|
—
|
—
|
—
|
—
|
—
|
|
2/28/19
|
(2)
|
—
|
—
|
—
|
—
|
9,428
|
—
|
—
|
1,275,891
|
|
2/28/19
|
(3)
|
—
|
—
|
17,510
|
52,530
|
—
|
—
|
—
|
2,587,803
|
Anne-Marie
|
2/28/19
|
(1)
|
486,500
|
973,000
|
—
|
—
|
—
|
—
|
—
|
—
|
Law
|
2/28/19
|
(2)
|
—
|
—
|
—
|
—
|
8,839
|
—
|
—
|
1,196,182
|
|
2/28/19
|
(3)
|
—
|
—
|
16,416
|
49,248
|
—
|
—
|
—
|
2,426,121
|
John Orloff
|
2/28/19
|
(1)
|
539,000
|
1,078,000
|
—
|
—
|
—
|
—
|
—
|
—
|
2/28/19
|
(2)
|
—
|
—
|
—
|
—
|
9,428
|
—
|
—
|
1,275,891
|
|
|
2/28/19
|
(3)
|
—
|
—
|
17,510
|
52,530
|
—
|
—
|
—
|
2,587,803
|
(1)
|
The amounts represent the annual cash incentive award target and maximum amounts for the NEO for 2019 multiplied by such individual's base salary. See "Annual Cash Incentive Awards" in the CD&A. Actual amounts paid to the NEO for 2019 are included in the "Non-Equity Incentive Plan Compensation" column under the "Summary Compensation Table" above. The maximum amount a NEO may earn is 200% of target bonus amount. The threshold values for this grant are excluded from the table as the minimum award value that could be received is zero.
|
(2)
|
The amount includes the number of shares of common stock underlying awards of RSUs granted to the NEO in 2019. These 2019 RSUs vest ratably on an annual basis over a four-year period.
|
(3)
|
The amount represents the estimated possible payouts for PSUs granted to the NEO in 2019. The maximum achievement amounts include additional shares that may be earned for the achievement of the relative TSR modifier of up to 27,633 for Dr. Hantson, 7,004 for Mr. Clancy, Mr. Goff and Dr. Orloff, 6,128 for Dr. Sarin and 6,566 for Ms. Law. In addition, the maximum achievement amounts include additional shares that may be earned for the achievement of different research and development (R&D) milestones over the award vesting period of up to 41,449 for Dr. Hantson, 10,506 for Mr. Clancy, Mr. Goff and Dr. Orloff, 9,193 for Dr. Sarin, and 9,849 for Ms. Law. The threshold values for this grant are excluded from the table above as the minimum award value that could be received is zero. To the extent earned based on performance, these 2019 PSUs cliff vest following the end of a three-year performance period.
|
(4)
|
The amount represents the grant date fair value of RSUs and PSUs granted in 2019 calculated in accordance with FASB ASC Topic 718, disregarding the effect of estimated forfeitures. For PSUs, the amounts represent the grant date fair value based on the probable outcome of the performance conditions on the grant date. See footnote 6 to the “Summary Compensation Table” above for the amounts included in respect of PSUs and the amounts that would be included if the highest level of performance conditions were achieved. See
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
78
|
(5)
|
Mr. Clancy's 2019 PSUs and unvested RSUs will be forfeited upon his departure in July 2020.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
79
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
80
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
81
|
Outstanding Equity Awards At 2019 Fiscal Year-End
|
|
|
Option Awards
|
Stock Awards
|
|||||||||
|
|
Number of Securities Underlying Unexercised Options
|
|
|
|
|
|
|
Equity Incentive Plan Awards:
|
|||
Name
|
Grant Date
|
Exercisable (#)
|
Unexercisable (#)
|
|
Option Exercise Price
($)
|
Option Expiration
Date |
Number of Shares or Units of Stock That Have Not Vested (#)
|
|
Market Value of Shares or Units of Stock That Have Not Vested
($)(1)
|
Number of Unearned Shares, Units, or Other Rights That Have Not Vested
(#)
|
|
Market or Payout Value of Unearned Shares or Units or Other Rights of Stock That Have Not Vested
($) (1)
|
Ludwig Hantson
|
03/27/17
|
39,023
|
17,739
|
(2)
|
118.83
|
03/27/27
|
14,363
|
(3)
|
1,553,358
|
—
|
|
—
|
03/27/17
|
—
|
—
|
|
—
|
—
|
31,752
|
(4)
|
3,433,979
|
—
|
|
—
|
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
26,820
|
(5)
|
2,900,583
|
—
|
|
—
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
66,411
|
(6)
|
7,182,350
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
37,198
|
(5)
|
4,022,964
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
69,082
|
(6)
|
7,471,218
|
Aradhana Sarin
|
11/29/17
|
—
|
—
|
|
—
|
—
|
5,820
|
(5)
|
629,433
|
—
|
|
—
|
02/28/18
|
—
|
—
|
|
—
|
—
|
2,533
|
(5)
|
273,944
|
|
|
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
6,274
|
(6)
|
678,533
|
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
8,250
|
(5)
|
892,238
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
15,321
|
(6)
|
1,656,966
|
Paul Clancy
|
07/10/17
|
16,363
|
12,726
|
(2)
|
123.76
|
07/10/27
|
23,432
|
(5)
|
2,534,171
|
—
|
|
—
|
07/10/17
|
—
|
—
|
|
—
|
—
|
16,076
|
(4)
|
1,738,619
|
—
|
|
—
|
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
7,152
|
(5)(7)
|
773,489
|
—
|
|
—
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
17,710
|
(6)(7)
|
1,915,337
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
9,428
|
(5)(7)
|
1,019,638
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
17,510
|
(6)(7)
|
1,893,707
|
Brian Goff
|
06/07/17
|
13,594
|
8,156
|
(2)
|
100.14
|
06/07/27
|
7,359
|
(5)
|
795,876
|
—
|
|
—
|
06/07/17
|
—
|
—
|
|
—
|
—
|
5,298
|
(4)
|
572,979
|
—
|
|
—
|
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
6,705
|
(5)
|
725,146
|
—
|
|
—
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
16,603
|
(6)
|
1,795,614
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
9,428
|
(5)
|
1,019,638
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
17,510
|
(6)
|
1,893,707
|
Anne-Marie Law
|
06/07/17
|
—
|
—
|
|
—
|
—
|
11,484
|
(5)
|
1,241,995
|
—
|
|
—
|
02/28/18
|
—
|
—
|
|
—
|
—
|
6,258
|
(5)
|
676,803
|
—
|
|
—
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
15,496
|
(6)
|
1,675,892
|
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
8,839
|
(5)
|
955,938
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
16,416
|
(6)
|
1,775,390
|
John Orloff
|
06/07/17
|
—
|
—
|
|
—
|
—
|
12,482
|
(5)
|
1,349,928
|
—
|
|
—
|
02/28/18
|
—
|
—
|
|
—
|
—
|
6,705
|
(5)
|
725,146
|
—
|
|
—
|
|
|
02/28/18
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
16,603
|
(6)
|
1,795,614
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
9,428
|
(5)
|
1,019,638
|
—
|
|
—
|
|
02/28/19
|
—
|
—
|
|
—
|
—
|
—
|
|
—
|
17,510
|
(6)
|
1,893,707
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
82
|
(1)
|
The market value of the stock awards is determined by multiplying the number of shares subject to such award times $108.15, which was the closing price of the Company's common stock as of December 31, 2019, the last business day of 2019.
|
(2)
|
Award of options that vest over a four-year period, with 25% vesting on the first anniversary of the date of grant and 6.25% vesting every three months thereafter, generally subject to continued employment or other service with the Company.
|
(3)
|
Award of RSUs that vests 25% on December 31, 2017, 25% on December 31, 2018, and then vest 25% on each of the third and fourth anniversary of the grant date, generally subject to continued employment or other service with the Company.
|
(4)
|
PSUs actually earned for the performance period ending December 31, 2017. One-third of the earned PSUs vested on February 6, 2018 and February 6, 2019 and the remaining unvested PSUs will vest on February 6, 2020, generally subject to continued employment or other service with the Company.
|
(6)
|
PSU awards granted in 2018 and 2019 are eligible to be earned based on performance during the performance period ending on December 31, 2020 and December 31, 2021, respectively. To the extent earned based on performance, the PSUs will vest on the third anniversary of the grant date, generally subject to continued employment or other service with the Company. Amounts have been reported in this table assuming target level achievement of performance goals. With respect to the PSUs granted in 2018, an additional 37.5% of the target award has been earned as of December 31, 2019 based on the achievement of R&D milestones. No R&D milestones have been earned as of December 31, 2019 with respect to the PSUs granted in 2019.
|
(7)
|
Mr. Clancy's 2018 and 2019 PSUs and any unvested RSUs will be forfeited upon his departure in July 2020.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
83
|
Option Exercises And Stock Vested For Fiscal 2019
|
|
|
Option Awards
|
Stock Awards
|
||||
Name
|
|
Number of Shares Acquired on Exercise
(#)
|
|
Value Realized on Exercise
($)
|
Number of Shares Acquired on Vesting
(#) (1)
|
|
Value Realized on Vesting
($)(2)
|
Ludwig Hantson
|
|
—
|
|
—
|
40,692
|
|
5,052,795
|
Aradhana Sarin
|
|
—
|
|
—
|
14,234
|
|
1,639,897
|
Paul Clancy
|
|
—
|
|
—
|
30,176
|
|
3,725,424
|
Brian Goff
|
|
—
|
|
—
|
11,213
|
|
1,379,270
|
Anne-Marie Law
|
|
—
|
|
—
|
7,828
|
|
962,151
|
John Orloff
|
|
—
|
|
—
|
8,476
|
|
1,041,397
|
(1)
|
Includes RSUs and PSUs that vested in 2019 as follows:
|
–
|
The number of shares subject to RSUs that vested in 2019: Dr. Hantson: 8,940, Dr. Sarin: 14,234, Mr. Clancy: 14,100, Mr. Goff: 5,915, Ms. Law: 7,828 and Dr. Orloff: 8,476.
|
–
|
One third of the PSUs earned for the performance period ending December 31, 2017 vested in 2019 as follows: Dr. Hantson: 31,752, Mr. Clancy: 16,076 and Mr. Goff: 5,298.
|
(2)
|
Amounts reflect the aggregate dollar amount realized upon vesting by multiplying the number of shares of stock vested by the closing price of the Company's common stock on the vesting date.
|
Name
|
Executive Contributions in Last Fiscal Year
($)(1)
|
|
Registrant Contributions in Last Fiscal Year ($)(2)
|
|
Aggregate Earnings in Last Fiscal Year
($)
|
|
Aggregate Withdrawals and Distributions
($)
|
|
Aggregate Balance at Last Fiscal Year End
($)(3)
|
Ludwig Hantson
|
—
|
|
—
|
|
3,722
|
|
—
|
|
19,173
|
Aradhana Sarin
|
60,402
|
|
2,200
|
|
20,202
|
|
—
|
|
133,767
|
Paul Clancy
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
Brian Goff
|
—
|
|
—
|
|
3,957
|
|
—
|
|
17,455
|
Anne-Marie Law
|
148,023
|
|
8,200
|
|
32,772
|
|
—
|
|
237,107
|
John Orloff
|
105,385
|
|
8,200
|
|
54,280
|
|
—
|
|
315,403
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
84
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
85
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
86
|
|
Cash Severance Payments(1)
|
Value of Accelerated Equity Awards (2)
|
Benefit Continuation Payments(3)
|
Total Termination Benefits(4)
|
Ludwig Hantson
|
|
|
|
|
n Death
|
$1,812,500
|
$26,564,452
|
$44,286
|
$28,421,238
|
n Disability
|
$1,500,000
|
$26,564,452
|
$44,286
|
$28,108,738
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$7,655,000
|
$4,987,337
|
$44,286
|
$12,686,623
|
n Involuntary termination after a change in control
|
$12,982,500
|
$26,564,452
|
$44,286
|
$39,591,238
|
Aradhana Sarin
|
|
|
|
|
n Death
|
$760,000
|
$4,131,114
|
$31,593
|
$4,922,707
|
n Disability
|
$560,000
|
$4,131,114
|
$31,593
|
$4,722,707
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$2,040,000
|
$629,433
|
$31,593
|
$2,701,026
|
n Involuntary termination after a change in control
|
$3,280,000
|
$4,131,114
|
$31,593
|
$7,442,707
|
Paul Clancy
|
|
|
|
|
n Death
|
$880,650
|
$9,874,961
|
27,093
|
$10,782,704
|
n Disability
|
$648,900
|
$9,874,961
|
27,093
|
$10,550,954
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$2,363,850
|
$4,272,790
|
27,093
|
$6,663,733
|
n Involuntary termination after a change in control
|
$3,800,000
|
$9,874,961
|
27,093
|
$13,702,754
|
Brian Goff
|
|
|
|
|
n Death
|
$703,000
|
$6,868,506
|
$31,593
|
$7,603,099
|
n Disability
|
$518,000
|
$6,868,506
|
$31,593
|
$7,418,099
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$1,887,000
|
$1,434,401
|
$31,593
|
$3,352,994
|
n Involuntary termination after a change in control
|
$3,034,000
|
$6,868,508
|
$31,593
|
$9,934,099
|
Anne-Marie Law
|
|
|
|
|
n Death
|
$660,250
|
$6,326,018
|
$31,593
|
$7,017,861
|
n Disability
|
$486,500
|
$6,326,018
|
$31,593
|
$6,844,111
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$1,772,250
|
$1,241,995
|
$31,593
|
$3,045,838
|
n Involuntary termination after a change in control
|
$2,849,500
|
$6,326,018
|
$31,593
|
$9,207,111
|
John Orloff
|
|
|
|
|
n Death
|
$731,500
|
$6,784,033
|
$31,593
|
$7,547,126
|
n Disability
|
$539,000
|
$6,784,033
|
$31,593
|
$7,354,626
|
n Change in Control
|
—
|
—
|
—
|
—
|
n Involuntary termination
|
$1,963,500
|
$1,349,928
|
$31,593
|
$3,345,021
|
n Involuntary termination after a change in control
|
$3,157,000
|
$6,784,033
|
$31,593
|
$9,972,626
|
(1)
|
Represents the cash severance amounts that would be payable as a result of the event described in the table above, based on the named executive officer’s base salary and target bonus amount as in effect on December 31, 2019, as applicable, and without including any accrued but unpaid compensation, paid time-off or any pay in lieu of any notice periods. The cash severance amounts that would be payable to each of our named executive officers in connection with a termination of employment under various circumstances is described in more detail below.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
87
|
(2)
|
Represents the value associated with cashing out unvested RSUs, earned PSUs and unearned PSUs, as applicable, and, that accelerate as a result of the event described in the table, based on a stock price of $108.15, which was the closing price of Alexion's common stock on December 31, 2019, the last business day of Alexion's 2018 fiscal year. No value associated with any stock options held by our named executive officers, other than Mr. Goff, is included in the table because all unvested stock options held by them as of December 31, 2019 had a per share exercise price that was in excess of the closing price of Alexion’s common stock on December 31, 2019. Mr. Goff's stock options were valued based on the number of shares associated with the vested and unexercised and the unvested portion of the award multiplied by the difference between $108.15, the closing price of Alexion's common stock on December 31, 2019, and the per share exercise price of the stock options. RSUs and PSUs were valued based on the number of shares associated with the unvested portion of each award multiplied by $108.15. Pursuant to their agreements, certain PSUs held by each of the named executive officers would vest to the extent determined in good faith by the Board based on achievement of the applicable performance conditions through termination of employment, as described in further detail under “Equity Awards” below. For purposes of this table, in connection with a change in control or death or disability termination, the value of any earned PSUs is based on the number of earned PSUs as of December 31, 2019 and any unearned PSUs are assumed to have vested at target levels. The actual amounts, if any, that will become payable with respect to outstanding unearned PSUs will be different.
|
(3)
|
Represents the estimated value of the lump sum cash payment that, after all applicable taxes and withholdings are deducted (assuming for this purpose a 42% tax rate), is the economic equivalent of the monthly health premiums paid by the Company on behalf of the named executive officer and his dependents as a result of the event described in the table, based on the cost of coverage under our benefit plans as of December 31, 2019.
|
(4)
|
Under their employment agreements, if amounts payable to each of our named executive officers are subject to an excise tax under Section 4999 of the Code, the amount payable will be the greater of (i) the payments reduced so that no portion of the payments are subject to such excise tax or (ii) the payments reduced by all applicable taxes, including such excise tax. For purposes of this table, it is assumed that no payments will be reduced under this provision.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
88
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
89
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
90
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
91
|
Director Compensation For Fiscal 2019
|
Name
|
Fees Earned or Paid in Cash
($)(1)
|
|
Stock Awards
($) (2)
|
|
Total
($)
|
Felix Baker
|
120,000
|
|
350,046
|
|
470,046
|
David Brennan
|
—
|
|
595,052
|
|
595,052
|
Christopher Coughlin
|
—
|
|
630,108
|
|
630,108
|
Deborah Dunsire
|
—
|
|
445,069
|
|
445,069
|
Paul Friedman
|
95,000
|
|
350,046
|
|
445,046
|
John Mollen
|
120,000
|
|
350,046
|
|
470,046
|
Francois Nader
|
95,000
|
|
350,046
|
|
445,046
|
Judy Reinsdorf
|
60,000
|
|
410,013
|
|
470,013
|
Andreas Rummelt
|
95,000
|
|
350,046
|
|
445,046
|
(1)
|
Represents retainer fees paid for services as a director during the fiscal year ended December 31, 2019. For 2019, these retainer fees were paid in cash or in the form of RSUs at the election of each director. If retainer fees were paid in RSUs, those are reflected in the Stock Awards column of the table.
|
(2)
|
Represents the grant date fair value of restricted stock units granted in 2019 calculated in accordance with FASB ASC Topic 718, disregarding the effects of estimated forfeitures. See Note 1 and Note 13 to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 for details as to the assumptions used to determine the fair value of the equity awards granted during the year ended December 31, 2019. The following non-employee directors held the following number of unvested RSUs as of December 31, 2019: Dr. Baker, 2,726; Mr. Brennan 3,680; Mr. Coughlin, 3,816; Dr. Dunsire, 2,911; Dr. Friedman, 2,726; Mr. Mollen, 2,726; Dr. Nader, 2,726; Ms. Reinsdorf, 2,959; and Dr. Rummelt, 2,726. The following non-employee directors held the following number of option awards as of December 31, 2019: Dr. Baker, 4,623; Mr. Brennan, 7,343; Mr. Coughlin, 7,343; Mr. Mollen,7,422; and Dr. Rummelt, 14,084.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
92
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
93
|
2019 Compensation Component
|
Value
|
Vehicle
|
Payment or Vesting Schedule
|
||
Annual Retainer (Non-Chairman)
|
$
|
95,000
|
|
Cash or shares of Alexion common stock
|
Quarterly
|
Annual Retainer (Chairman)
|
$
|
245,000
|
|
Cash or shares of Alexion common stock
|
Quarterly
|
Chair of Audit and Finance Committee
|
$
|
35,000
|
|
Cash or shares of Alexion common stock
|
Quarterly
|
Chair of all other committees
|
$
|
25,000
|
|
Cash or shares of Alexion common stock
|
Quarterly
|
Annual Equity Award1
|
$
|
350,000
|
|
Shares of Alexion common stock
|
One Year from Grant
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
94
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
95
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
96
|
Independent Registered Public Accounting Firm
|
Fees
|
|
Year Ended
|
|
Year Ended
|
|
December 31, 2019
|
|
December 31, 2018
|
|
Audit fees (1)
|
|
$5,333,815
|
|
$4,384,965
|
Audit-related fees (2)
|
|
$5,000
|
|
$229,840
|
Tax fees (3)
|
|
$40,000
|
|
$110,334
|
All other fees (4)
|
|
$9,900
|
|
$9,900
|
|
|
$5,388,715
|
|
$4,735,039
|
(1)
|
Audit fees include fees billed and expected to be billed by PricewaterhouseCoopers LLP for professional services rendered for the audit of Alexion's annual financial statements included in its Annual Report on Form 10-K, the review of Alexion's financial statements included in its Quarterly Reports on Form 10-Q, as well as professional services rendered in conjunction with acquisitions and other strategic transactions, services related to other SEC filings and statutory audits.
|
(2)
|
Audit-related fees for the year ended December 31, 2018 primarily include fees billed by PricewaterhouseCoopers LLP for professional services rendered in conjunction with new accounting pronouncements.
|
(3)
|
Tax services billed for the year ended December 31, 2019 and 2018 primarily include tax support services.
|
(4)
|
All other fees for the year ended December 31, 2019 and 2018 primarily include fees for accounting research software provided by PricewaterhouseCoopers LLP.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
97
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
98
|
Proposal No. 2 – Ratification Of Appointment Of Independent Registered Public Accounting Firm
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
99
|
Proposal No. 3 – Advisory Vote on Executive Compensation
|
•
|
Pay for performance, reward company and individual achievement, and align the interests of our executives with those of our shareholders;
|
•
|
Establish incentive performance goals that encompass financial, operational, strategic, and shareholder return metrics ensuring executive focus on broad-based strategic execution and links payouts realized by executives to strong financial performance and long-term value creation;
|
•
|
Ensure compensation programs are structured to attract, retain and motivate the best talent;
|
•
|
Ensure compensation is competitive with the companies that compete with us for talent;
|
•
|
Maintain an appropriate composition allocation between cash and equity incentives, with increasing weighting toward equity compensation (and towards performance equity awards); and
|
•
|
Be fair and consistent.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
100
|
Proposal No. 4 - Shareholder Proposal Requesting The Board To Amend Alexion’s Governing Documents to Give Shareholders Owning 10% of Alexion Stock The Power to Call A Special Meeting
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
101
|
•
|
Importantly, Alexion’s shareholders already have the right to act by written consent in between annual meetings, without calling a special meeting.
|
•
|
Alexion’s shareholders may suggest director nominees to the Nominating and Corporate Governance Committee for consideration or through proxy access provisions in our Bylaws.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
102
|
•
|
Alexion’s Board is declassified and all directors stand for re-election annually.
|
•
|
Alexion has a majority voting standard for the election of directors - directors must receive a majority of votes entitled to vote in uncontested elections.
|
•
|
Alexion has undertaken substantial board refreshment and effective director succession planning in recent years, resulting in four new independent directors being appointed since 2017 and six of the Board’s nine independent directors having a tenure of under five years. Alexion’s Board composition is aligned with Alexion’s business strategies, industry positioning and risk oversight priorities.
|
•
|
We have a robust shareholder engagement program and regularly seek - and incorporate - shareholder input.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
103
|
Beneficial Ownership Of Common Stock
|
Name and Address of Beneficial Owner (1)
|
|
Number of Shares of Common Stock Beneficially Owned (2)
|
|
Percentage of Outstanding Shares of Common Stock
|
The Vanguard Group (3)
|
|
|
|
|
100 Vanguard Blvd.
|
|
|
|
|
Malvern, PA 19355
|
|
16,764,417
|
|
7.57
|
Blackrock, Inc. (4)
|
|
|
|
|
55 East 52nd Street
|
|
|
|
|
New York NY 10055
|
|
15,913,371
|
|
7.20
|
FMR LLC (5)
|
|
|
|
|
245 Summer Street
|
|
|
|
|
Boston, MA 02210
|
|
14,805,724
|
|
6.69
|
State Street Corporation (6)
|
|
|
|
|
1 Lincoln Street
|
|
|
|
|
Boston, MA 02111
|
|
11,348,358
|
|
5.13
|
T. Rowe Price Associates, Inc. (7)
|
|
|
|
|
100 E. Pratt Street
|
|
|
|
|
Baltimore, MD 21202
|
|
12,105,898
|
|
5.40
|
Ludwig Hantson (8)(20)
|
|
139,941
|
|
*
|
Paul Clancy (9)(20)
|
|
67,229
|
|
*
|
Brian Goff (10)(20)
|
|
34,835
|
|
*
|
Anne-Marie Law (20)
|
|
11,965
|
|
*
|
John Orloff (20)
|
|
12,480
|
|
*
|
Aradhana Sarin (20)
|
|
10,439
|
|
*
|
Felix Baker(11)
|
|
8,503,343
|
|
3.83
|
David Brennan (12)
|
|
16,681
|
|
*
|
Christopher Coughlin (13)
|
|
38,454
|
|
*
|
Deborah Dunsire (14)
|
|
7,725
|
|
*
|
Paul Friedman (15)
|
|
6,877
|
|
*
|
John Mollen (16)
|
|
15,187
|
|
*
|
Francois Nader (17)
|
|
6,877
|
|
*
|
Judith Reinsdorf (18)
|
|
7,452
|
|
*
|
Andreas Rummelt (19)
|
|
36,230
|
|
*
|
All directors and executive officers as a group (18 persons) (21)
|
|
8,947,946
|
|
4.03
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
104
|
(1)
|
Unless otherwise indicated, the address of all persons is 121 Seaport Boulevard, Boston, MA 02210.
|
(2)
|
To our knowledge, except as set forth below, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and the information contained in the footnotes in this table.
|
(3)
|
These figures are based upon information set forth in Schedule 13G filed with the SEC on February 12, 2020. Vanguard Group Inc. has sole voting power with respect to 338,575 of the shares listed and sole dispositive power over all of the shares.
|
(4)
|
These figures are based upon information set forth in Schedule 13G filed with the SEC on February 5, 2020. BlackRock, Inc. has sole voting power with respect to 14,083,488 of the shares listed and sole dispositive power over all of the shares.
|
(5)
|
These figures are based upon information set forth in Schedule 13G filed with the SEC on January 10, 2020. FMR LLC has sole voting power with respect to 1,369,806 of the shares listed and sole dispositive power over all of the shares.
|
(6)
|
These figures are based upon information set forth in Schedule 13G filed with the SEC on February 13, 2020. State Street Corp has zero shares of sole voting power with respect to the shares listed and sole dispositive power over all of the shares.
|
(7)
|
These figures are based upon information set forth in Schedule 13G filed with the SEC on February 14, 2020 These securities are owned by various individual and institutional investors which T. Rowe Price Associates, Inc., or Price Associates, serves as investment advisor with power to direct investments and/or sole power to vote the securities. Price Associates has sole voting power with respect to 4,227,734 of the shares listed and sole dispositive power over all of the shares. For the purposes of the reporting requirements of the Securities Exchange Act of 1934, Price Associates is deemed to be a beneficial owner of such securities; however, Price Associates expressly disclaims that it is, in fact, the beneficial owner of such securities.
|
(8)
|
Includes 7,181 shares of common stock which will be acquired by Dr. Hantson upon the vesting of restricted stock units that will vest within 60 days of March 15, 2020 and 42,571 shares of common stock which may be acquired by Dr. Hantson upon the exercise of stock options that are exercisable within 60 days of March 15, 2020.
|
(9)
|
Includes 19,999 shares of common stock which may be acquired by Mr. Clancy upon the exercise of stock options that are exercisable within 60 days of March 15, 2020.
|
(10)
|
Includes 14,954 shares of common stock which may be acquired by Mr. Goff upon the exercise of stock options that are exercisable within 60 days of March 15, 2020.
|
(19)
|
Includes 2,726 shares of common stock which will be acquired by Dr. Rummelt upon the vesting of restricted stock units that will vest within 60 days of March 15, 2020 and 14,084 shares of common stock which may be acquired by Dr. Rummelt upon the exercise of options that are exercisable within 60 days of March 15, 2020.
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
105
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
106
|
Additional Information
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
107
|
2019 Proxy Statement Alexion Pharmaceuticals, Inc.
|
108
|
Appendix A
|
|
Twelve months ended
|
||||||||||
|
December 31
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
GAAP net income
|
$
|
2,404.3
|
|
|
$
|
77.6
|
|
|
$
|
443.3
|
|
Before tax adjustments:
|
|
|
|
|
|
||||||
Cost of sales:
|
|
|
|
|
|
||||||
Share-based compensation
|
14.2
|
|
|
16.0
|
|
|
11.1
|
|
|||
Fair value adjustment in inventory acquired
|
—
|
|
|
—
|
|
|
5.2
|
|
|||
Restructuring related expenses
|
—
|
|
|
5.8
|
|
|
152.1
|
|
|||
Research and development expense:
|
|
|
|
|
|
||||||
Share-based compensation
|
61.7
|
|
|
57.4
|
|
|
76.4
|
|
|||
Upfront payments related to licenses and other strategic agreements
|
103.4
|
|
|
26.7
|
|
|
49.4
|
|
|||
Restructuring related expenses
|
—
|
|
|
0.1
|
|
|
16.3
|
|
|||
Selling, general and administrative expense:
|
|
|
|
|
|
||||||
Share-based compensation
|
161.1
|
|
|
129.6
|
|
|
155.7
|
|
|||
Restructuring related expenses
|
—
|
|
|
19.4
|
|
|
10.9
|
|
|||
Litigation charges
|
0.1
|
|
|
13.0
|
|
|
—
|
|
|||
Gain on sale of asset
|
—
|
|
|
(3.5
|
)
|
|
—
|
|
|||
Acquired in-process research and development
|
(4.1
|
)
|
|
1,183.0
|
|
|
—
|
|
|||
Amortization of purchased intangible assets
|
309.6
|
|
|
320.1
|
|
|
320.1
|
|
|||
Change in fair value of contingent consideration
|
11.6
|
|
|
116.5
|
|
|
41.0
|
|
|||
Restructuring expenses
|
12.0
|
|
|
25.5
|
|
|
104.6
|
|
|||
Impairment of intangible assets
|
—
|
|
|
—
|
|
|
31.0
|
|
|||
Investment income (expense):
|
|
|
|
|
|
||||||
(Gains) and losses related to strategic equity investments
|
(59.7
|
)
|
|
(43.1
|
)
|
|
—
|
|
|||
Other income and (expense):
|
|
|
|
|
|
||||||
Gain related to purchase option
|
(32.0
|
)
|
|
—
|
|
|
—
|
|
|||
Restructuring related expenses
|
—
|
|
|
(0.1
|
)
|
|
2.6
|
|
|||
Adjustments to income tax expense
|
(584.9
|
)
|
|
(145.4
|
)
|
|
(82.2
|
)
|
|||
Non-GAAP net income
|
$
|
2,397.3
|
|
|
$
|
1,798.6
|
|
|
$
|
1,337.5
|
|
|
|
|
|
|
|
||||||
GAAP earnings (loss) per common share - diluted
|
$
|
10.70
|
|
|
$
|
0.35
|
|
|
$
|
1.97
|
|
Non-GAAP earnings per common share - diluted
|
$
|
10.53
|
|
|
$
|
7.92
|
|
|
$
|
5.86
|
|
|
|
|
|
|
|
||||||
Shares used in computing diluted earnings per common share (GAAP)
|
224.8
|
|
|
224.5
|
|
|
225.4
|
|
|||
Shares used in computing diluted earnings per common share (non-GAAP)
|
227.6
|
|
|
227.1
|
|
|
228.1
|
|
Form Of Proxy Card
|
1
|
Proposal – Election of Directors-Nominees are:
|
2
|
Proposal No. 2 – Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.
|
3
|
Proposal No. 3 – Approval of a non-binding advisory vote of the 2019 compensation paid to Alexion's named executive officers.
|
4
|
Proposal No. 4 – Shareholder Proposal requesting certain By-law amendments to lower the threshold for shareholders to call a special meeting.
|